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Chronic kidney disease (CKD) is increasingly recognized as a global 
public health problem. Cardiovascular disease (CVD) is a major cause of 
mortality in patients with mild to moderate CKD and end-stage renal disease 
(ESRD). There is accumulating evidence that the increase in CVD burden is 
present in CKD patients prior to dialysis, due to both conventional risk factors 
as well as those specific to kidney disease. Detection and initiation of 
treatment for CVD risk factors at earlier stages of CKD should be effective in 
reducing CVD events both before and after the onset of kidney failure. 
Therefore, this study aimed to assess a group of traditional CVD risk factors 
including, hypertension, diabetes, dyslipidemia, physical inactivity, body mass 
index (BMI), family history of CVD, and CKD-specific CVD risk factors 
including, hypoalbuminemia, albuminuria, anemia, Ca x P product, and 
inflammation (C-reactive protein), in CKD patients in Gaza strip, aged ≤12  
years old and haven't undergone  kidney replacement therapy.  
Patients of the study (40 male and 20 female) were categorized into 4 
stages (2, 3, 4, and 5) where stage 1 was not encountered. Stage 4 had the 
highest distribution, followed by stage 3, stage 5 and stage 2. There were 
statistically significant differences between patients and controls in the terms 
of height, weight, systolic blood pressure (SBP), and diastolic blood pressure 
(DBP), where the mean values indicated that the patients were shorter, had 
lower weight, higher SBP and DBP with 47% of the patients having 
hypertension. Frequency of physical inactivity among patients was 2-fold 
higher as compared to controls (50% vs. 25%). As compared to controls, 
patients had significantly higher means of cholesterol (163.6 ±39.8 vs. 141.8 
±24.2 mg/dl, p=0.001), triglycerides (145.5 ±67.1 vs. 82.9 ±39.8 mg/dl, 
p=0.000), Low density lipoprotein (LDL) (92.6 ±31.9 vs. 72.5 ±19 mg/dl, 
p=0.000), and they had lower means of high density lipoprotein (HDL) (41.9 
±11.0 vs. 52.7 ±11.7 mg/dl, p=0.000). As compared to controls, patients had 
significantly lower hemoglobin (9.8 ±1.4 vs. 11.9 ±0.8 g/dl, p=0.000), albumin 
(4.6 ±0.6 vs. 4.8 ±0.2 g/dl, p=0.012) and higher albumin/creatinine ratio (ACR) 
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(1792 ±3183 vs. 11.1 ±6.6 mg/g, p=0.000). C- reactive protein (CRP) showed 
high occurrence among patients (40% were positive for CRP). Calcium and 
phosphorus evaluation showed significantly lower calcium and higher 
phosphorus among patients. However, Ca X P product was not statistically 
significant in patients compared to controls (52.4 vs. 53.4 mg2/dl2, p= 0.582).  
This study indicates that many of the CVD risk factors are associated 
with different stages of CKD in children patients prior to dialysis, and that 
these factors are exacerbated as CKD progresses. 
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دموية بين األطفال المصابين بمرض الكلى عوامل خطر اإلصابة بأمراض القلب واألوعية ال
 المزمن في قطاع غزة
 
 المستخلص
 القلب واألوعية ضتعتبر أمرا.  مشكلة صحية عالمية عامة يمثلمرض الكلى المزمن
 مرض الكلى المزمن الدموية هي السبب الرئيسي للوفيات لدى المرضى الذين يعانون من
دالئل تظهر هناك . )الفشل الكلوي(ية ئنها المرحلة المعتدلة وال إلىخفيفة ال بمراحله المختلفة
موجود في مرضى الكلى المزمن قبل  الدموية واألوعية عبء مرض القلب أن الزيادة في
الغسيل الكلوي وذلك بسبب وجود عوامل خطر مرض القلب و األوعية الدموية التقليدية 
شف والشروع في معالجة كال لذلك فان .فضال عن تلك الناشئة عن مرض الكلى المزمن
 له مرض الكلى المزمن  الدموية في مراحل مبكرة منواألوعيةعوامل الخطر لمرض القلب 
  . الدموية قبل وبعد حدوث الفشل الكلويواألوعية في الحد من مرض القلب فاعلية
عوامل خطر مرض القلب و األوعية تقييم مجموعة من إلى تهدف هذه الدراسة 
،  اضطراب مكونات الدهون السكري، مرضارتفاع ضغط الدم، وتتضمن الدموية التقليدية
، إضافة  الدمويةواألوعية كتلة الجسم، والتاريخ العائلي لمرض القلب معاملالخمول البدني، 
الزالل البولي، نقص الزالل   زيادة،مثل إلى عوامل الخطر الناشئة عن مرض الكلى المزمن
 و ذلك في األطفال الذين ،لسيوم والفوسفور، و االلتهاباتناتج ضرب الكا فقر الدم، الدموي،
و الذين لم يخضعوا للغسيل الكلوي  أو  في قطاع غزة ، يعانون من مرض الكلى المزمن
  .لزراعة الكلى
  من المرض مراحلأربعة إلى واصنف)  أنثى20 ذكر و 40(لدراسة امرضى 
لم تكن موجودة في عينة  األولىالمرحلة  .)المرحلة الثانية، الثالثة، الرابعة، و الخامسة(
 ، الثالثة، تليها المرحلة المرحلة الرابعة كانت تحتوي على أعلى نسبة من المرضى. الدراسة
 بين إحصائيةكانت هناك فروق ذات داللة . الثانيةمرحلة ال و أخيرا،  المرحلة الخامسةثم
دم االنقباضي و ضغط الدم  الطول والوزن وضغط الالعينة الضابطة في كل منالمرضى و
و أكثر  أقصر وأقل وزنا  كانوا أن المرضىأن متوسط القيم أشار إلى، حيث االنبساطي
  . من العينة الضابطةضغط الدمل اارتفاع
نسبة الخمول .  من المرضى يعانون من ارتفاع ضغط الدمةسبعة و أربعون في المائ
مقارنة %). 25مقابل % 50(لضابطة البدني بين المرضى كانت ضعف النسبة في العينة ا
بالعينة الضابطة، فان متوسط الكولستيرول، الدهون الثالثية والدهون قليلة الكثافة كانت اعلي، 
 v
عوامل خطر مرض القلب . بينما كانت الدهون عالية الكثافة اقل وبفروق ذات داللة احصائية
ت داللة إحصائية بين و األوعية الدموية الناشئة عن مرض الكلى أظهرت فروقات ذا
المرضى والعينة الضابطة في كل من فقر الدم، زيادة الزالل البولي، نقص الزالل الدموي، و 
كما أظهرت الدراسة انه لم يكن هناك فرق ذو داللة إحصائية بين المرضى و . االلتهابات
  .  العينة الضابطة في نتائج حاصل ضرب الكالسيوم و الفسفور
 مراض القلب واألوعية الدمويةألالكثير من عوامل الخطر دراسة أن نستنتج من هذه ال
غسيل ال تكون مصاحبة لمرض الكلى المزمن بمراحله المختلفة عند األطفال المصابين قبل
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Definition of terms 
 
Family history of cardiovascular disease 
 Any one of the patient's close relatives had heart attack, heart bypass 
surgery, heart angioplasty, stroke, heart failure, abnormal heart rhythm, or 
peripheral arterial disease (McFarlane et al., 2008). 
 
Body mass index (BMI) 
Body mass index is defined as a measurement of the relative percentages of 
fat and muscle mass in the human body, in which weight in kilograms is 
divided by height in squared meters and the result is used as an index of 
obesity (World Health Organization, WHO, 2000). 
 
Classification of BMI According to WHO: 
Underweight <18.5  kg/m2 
Normal weight 18.5 - 24.9  kg/m2 
Overweight 25 - 29.9  kg/m2 
Obesity ≥ 30  kg/m2 




Dyslipidemia is any abnormality in plasma lipoprotein concentration or 
composition that is associated with an increased risk for atherosclerotic 
cardiovascular disease (ACVD) (National Kidney Foundation, NKF, 2003). 
 
Levels in term of risk for cardiovascular disease in children 
 (Palestinian clinical laboratory tests guide, PCLTG, 2005) 
Critical value risk 170-199 mg/dl 
Cholesterol 
High risk ≥ 200 mg/dl 
Triglycerides  ≥ 200 mg/dl 
High density lipoprotein High risk ≤ 35 mg/dl 
Moderate risk   110-129 mg/dl 
Low density lipoprotein 
High risk ≥ 130 mg/dl 
 xvi
Anemia  
 The Kidney Disease Outcomes Quality Initiative (KDOQI) defined 
anemia in children as hemoglobin <11.0 g/dL (Feber and Wong, 2007). 
 
Albuminurea 
 Albuminuria is defined as an albumin-to-creatinine ratio (ACR) in 
untimed “spot” urine samples of 30 mg/g or higher. 
• Microalbuminuria is defined as an albumin-to-creatinine ratio of 30 to 
300 mg/g.  
• Macroalbuminuria is defined as an albumin-to-creatinine ratio over 
300 mg/g (Sarnak et al., 2003; ADA, 2004; K/DOQI, 2004 and Coresh 
et al., 2007). 
 
Calcium- phosphorus product 
Blood Ca X P (expressed in mg2/dL2) is the result of multiplying the 
total calcium in mg/dl with phosphorus in mg/dl. If serum levels of albumin are 
low, a correction of the measured serum levels of calcium should be made. 
Corrected total calcium (mg/dL) = Total calcium (mg/dL) + 0.8 × [4 − Serum 
albumin (g/dL)]. The goal level of Ca X P should be below 65 in infants and 
























Chronic kidney disease (CKD) is defined as kidney  damage for ≥ 3 
months, as confirmed by kidney biopsy or markers of kidney damage, with or 
without a decrease in glomerular filtration rate (GFR) or GFR < 60 
mL/min/1.73 m2  for ≥ 3 months, with or without kidney damage (NKF, 2002). 
Chronic kidney disease is now being recognized as a major public health 
problem that is threatening to reach epidemic proportions over the next 
decades (lysaght, 2002). In children CKD carries a significant impact. The 
mortality that is associated with end stage renal disease (ESRD) in children 
who receive dialysis is estimated to be at least 30 times higher than that in 
the general pediatric population. Unlike adults, who have completed their 
physiologic and intellectual maturation, children are in formative stages of 
development and therefore are particularly susceptible to the adverse effects 
of CKD (Furth et al., 2006). 
Chronic kidney disease represents a developing process that is initiated 
by various causes, all with the common end result of persistent and usually 
progressive damage of varying severity to the kidney. These patients have a 
continuous decline in renal function and hence are said to have progressive 
renal failure (Vijayakumar et al., 2007). 
As kidney disease advances and the glomerular filtration rate (GFR) 
declines, almost all of the body’s systems are adversely affected. The major 
complications of chronic kidney disease are: cardiovascular disease (CVD), 
renal osteodystrophy, anemia, and nutritional disturbances (Cassidy et al., 
2007). Cardiovascular disease remains the leading cause of morbidity and 
mortality in patients with ESRD. Both in dialysis and in transplant patients, 
CVD remains the leading cause of death (Levin, 2008).  
The earlier observations on the relationship between renal failure and 
increased rates for cardiovascular complications and death date back to 
several decades (Ma, 1975). Approximately 50% of mortality in the dialysis 
population is due to CVD and the risk of death from CVD is elevated 30- fold 
for patients with ESRD compared with the general population (Querfeld, 
2002). Cardiovascular morbidity and even mortality seems to be prevalent 
also among children and adolescents with ESRD, despite much lower 
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exposure to “classical” risk factors for atherosclerosis, such as diabetes, 
smoking, and hyperlipidemia (Litwin et al., 2005).  
There is accumulating evidence that the increase in CVD burden is 
present in patients prior to dialysis, due to both conventional risk factors as 
well as those specific to kidney disease (Levin, 2008). Risk factors for the 
increased prevalence of CVD in CKD include traditional factors: age, sex, 
diabetes, hypertension, smoking, obesity and those specific to CKD: blood 
pressure changes, fluid imbalance, calcium/phosphorus metabolism, anemia, 
malnutrition, hypoalbuminemia, hyperhomocysteinemia, inflammation, oxidant 
stress, insulin resistance, altered renin angiotensin axis and endothelial 
dysfunction (Amaresan, 2005). 
Children with CKD have a high lifetime exposure to risk factors for CVD, 
it is very important to treat modifiable factors that contribute to CVD in 
children. However, early detection and aggressive management of CKD-
related complications will reduce the progression of the disease and improve 
the growth and development of the patient (Gulati, 2008). 
The present study was conducted in order to investigate the association 
between different stages of CKD and common CVD risk factors, such as, 
diabetes, hypertension, dyslipidemia, Ca x P product, hypoalbuminemia, 
albuminuria, anemia, inflammation (C-reactive protein), physical inactivity, 
body mass index (BMI), and family history of CVD in children with CKD in 
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1.2 Aim of the study 
The overall aim of the present study is to investigate the association 
between various risk factors of CVD and different stages of CKD in 
children patients without kidney replacement therapy in Gaza strip.  
     The specific objectives are: 
• To classify the CKD patients into 5 stages according to GFR and 
albuminuria.   
• To correlate laboratory findings with CKD classes. 
• To determine the main cardiovascular risk factors in the patients. 




• This study is carried out for the first time among children with CKD in 
Gaza strip, children constitute about half of the Gaza strip population 
(Palestinian Health Information Center, PHIC, 2005).  
• Identification of CVD risk factors among patients with CKD is 
potentially useful for raising awareness of the relationship between 
CKD and CVD.  
• Encouragement of clinicians to evaluate their CKD patients for CV risk 
factors, such risk factors may be used in monitoring the progression of 
the disease and predicting the future events.  
• Initiation of treatment for CV risk factors at earlier stages of CKD, 
which may be effective in reducing CVD events both before and after 
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2.1 The Kidneys 
2.1.1 Location and structure 
The kidneys lie against the dorsal body wall beneath the parietal 
peritoneum in superior lumbar region where they receive some protection from 
the lower part of the rib cage. The right kidney is positioned slightly lower than 
the left kidney. Each kidney (about 12.5 cm long, 7.5 cm wide and 2.5 cm thick) 
has a medial indentation (the hilus) in which there is two renal arteries, renal 
vein, and ureter. A fibrous renal capsule encloses each kidney. The kidney has 
three regions, outer granulated layer called renal cortex, renal medulla that 
consists of cone shaped tissue masses called medullary pyramids, and renal 
pelvis which is a central space or cavity that is continuous with the ureter  
(Figure 2.1) (Marieb, 2003).   
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Each kidney contains approximately one million tiny structures called 
nephrons (Figure 2.2). Nephrons are responsible for the processes of filtration, 
reabsorption, and secretion that go on in the kidney to form the urine product. 
The nephron consists of two main structures, a glomerulus, which is a knot of 
capillaries, and a renal tubule. The closed end of the renal tubule is enlarged 
and cup-shaped and completely surrounds the glomerulus. This portion of the 
renal tubule is called Bowman's capsule. In order from Bowman's capsule they 
are the proximal convoluted tubule, loop of Henle, and the distal convoluted 
tubule. Most of the nephron is located in the cortex, only portion of the loops of 
Henle dip into the medulla. Urine from many nephrons is collected in the 
collecting ducts, which deliver the final urine product into the calyces and pelvis 




Figure 2.2. Structure of the nephron 
 
Every nephron is associated with two capillary beds: The glomerulus and 
the peritubular capillary bed. The glomerulus is both fed and drained by 
arterioles. The afferent arteriole is the feeder vessel, and the efferent arteriole 
receives blood that has passed through the glomerulus. The efferent arteriole 
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then breaks up to form the peritubular capillary bed, which closely clings to the 
whole length of the tubule. The peritubular capillaries then drain into an 
interlobular vein that leaves the cortex (Marieb, 2003). 
 
2.1.2 Role of the kidneys 
The kidneys perform two main functions: eliminate soluble waste products 
of metabolism and preserve the internal environment of the cells (maintain 
water balance, pH, ionic equilibrium, and fluid osmotic pressure). In addition,  
the kidney does perform other functions such as, synthesis of erythropoietin, a 
hormone stimulating red blood cell production, and 1-hydroxylation of 25-
hydroxy-vitamin D3 (Kaplan and Szabo,1983). 
 
2.1.3 Principles of renal pathophysiology 
Renal injury can be characterized as either acute or chronic. Each has a 
distinctive clinical expression. 
 
2.1.3.1 Acute renal failure 
Acute renal failure (ARF) is defined as ″a rapid decline in renal filtration 
function″. This condition is usually marked by a rise in serum creatinine 
concentration or azotemia (a rise in blood urea nitrogen concentration) 
immediately after a kidney injury. Emergency dialysis may be needed until the 
situation resolves and the kidneys begin functioning again (Agraharkar, 2007). 
Acute renal insufficiency typically presents with the symptoms of volume 
overload secondary to impaired urine formation or excretion (Glassock, 1987). 
The consequent retention of sodium and therefore of water can cause an 
expansion of the intravascular spaces and extravasation of fluid into the 
interstitial space throughout the body. The resulting volume expansion can 
therefore present as peripheral edema, pulmonary edema, or congestive heart 
failure. In acute renal failure both acidemia (resulting from failure to excrete or 
buffer the endogenous metabolic production of acids) and hyperkalemia 
(resulting from the lack of excretion of dietary potassium) can result in cardiac 
arrhythmias and sudden death. Acute uremia has a particularly inhibitory effect 
on platelet function resulting in increase in the bleeding tendency (Kissane and 
Schreiner, 1990). 
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2.1.3.2 Chronic renal failure 
In chronic renal failure the metabolic consequences of uremia are slowly 
progressive in nature (Glassock, 1987). Chronic acidosis can affect myocardial 
contractility; contribute to central nervous system toxicity. Water and salt intake 
persistently exceeds excretory capacity, edema formation occurs. Chronic 
sodium retention can manifest as persistent arterial hypertension. Kidney also 
fails to convert 25-hydroxyvitamin D to the metabolically active 1, 25-
dihydroxyvitamin D, resulting in the defective absorption of calcium from the 
intestinal tract; secondary hypocalcemia induces secondary 
hyperparathyroidism with concomitant demineralization and resorption of bone. 
Depression of red cell production is the consequence of decreased renal 
production of the hormone erythropoietin. Increased red blood cell destruction 
resulting from uremic toxins as well as the mechanical damage to red cell 
observed in a variety of glomerular disease. Finally, patients with chronic 
kidney failure had depressed cellular immunity and humoral immunity (Kissane 
and Schreiner, 1990). 
 
2.2 Chronic kidney disease 
2.2.1 Definition of CKD 
The National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF-KDOQI) in the USA defines CKD as ″kidney  damage for ≥ 3 
months, as confirmed by kidney biopsy or markers of kidney damage, with or 
without a decrease in GFR or GFR < 60 mL/min/1.73 m2 for ≥ 3 months, with or 
without kidney damage″. Kidney damage is ascertained by either kidney biopsy 
or markers of kidney damage, such as urine abnormalities (proteinuria), blood 
abnormalities or abnormalities on imaging studies (NKF, 2002). 
 
Glomerular filtration rate provides an excellent measure of the filtering 
capacity of the kidneys. A low or decreasing GFR is a good index of CKD. 
Since the total kidney GFR is equal to the sum of the filtration rates in each of 
the functioning nephrons, the total GFR can be used as an index of functioning 




Chapter 2                                                                                    Literature Review    
8 
Table 2.1 Normal glomerular filtration rate in children and adolescents. 
                   Age                                             Mean GFR±SD (mL/min/1.73 m2) 
1 week (males and females)                                          41±15 
2–8 weeks (males and females)                                    66±25 
>8 weeks (males and females)                                      96±22 
2–12 years (males and females)                                 133±27 
13–21 years (males)                                                     140±30 
13–21 years (females)                                             126±22 
*Adopted from NKF, 2002. 
 
 
A decrease in GFR precedes kidney failure in all forms of progressive 
kidney diseases. Monitoring changes in GFR can delineate progression of 
kidney disease. The level of GFR is a strong predictor of the time of onset of 
kidney failure as well as the risk of complications of CKD (NKF, 2002). The 
level of GFR should be estimated from prediction equations that take into 
account the serum creatinine concentration and some or all of the following 
variables: age, gender, race, and body size (Table 2.2). The following 
equations provide useful estimates of GFR: 
• In children, the Schwartz and Counahan-Barratt equations 
• In adults, the abbreviated Modification of Diet in Renal Disease (MDRD) 
Study equation and Cockcroft-Gault equations (NKF, 2002). 
 
Table 2.2 Prediction of glomerular filtration rate based on serum creatinine 
Equation Author Equation 
Schwartz 
 
GFR (ml/mim/1.73m²) =  0.55×length  ⁄ Scr 
Counahan-Barratt 
 
GFR (ml/mim/1.73m²) =  0.43 × length  ⁄ Scr 
Abbreviated MDRD Study GFR(ml/mim/1.73m²)=186×(Scr)×(Age)×(0.742 if 
female) × (1.210 if black) 
Cockcroft-Gault Ccr (ml/min) =  (140 – Age)×Weight ×(0.85 if female ) ⁄ 
72× Scr 
Scr: serum creatinine, Ccr: creatinine clearance 
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Proteinuria not only defines the presence of CKD but also has important 
implications for diagnosis of the type of kidney disease and is associated with a 
worse prognosis for both kidney disease progression and the development of 
CVD (Sarnak et al., 2003). Twenty-four hour or other timed collections were the 
traditional way to measure urine albumin excretion (UAE) but measuring urine 
albumin/creatinine ratio (ACR) in a spot collection of morning urine in the 
fasting state is currently recommended as a simple, quick and comparatively 
accurate way of determining albuminuria (Levey et al., 2003; American 
Diabetes Association, 2004; Busby and Bakris, 2004). Albuminuria is defined 
as an ″ACR of 30 mg/g or higher″, with microalbuminuria defined as an ″ACR of 
30 to 300 mg/g″, and macroalbuminuria defined as an ″ACR over 300 mg/g″ 
(Coresh et al., 2007). 
 
2.2.2 Classification of CKD 
Chronic kidney disease has been classified into various stages for the 
purpose of prevention, early identification of renal damage and institution of 
preventive measures for progression of the primary damage and appropriate 
guidelines for instituting management for prevention of complications in severe 
CKD (Vijayakumar et al., 2007). National kidney foundation classified CKD into 
5 stages according to the level of GFR (Table 2.3). For stages 1 and 2, kidney 
damage was assessed by spot albumin-to-creatinine ratio (NKF, 2002). 
 
Table 2.3 Classification of the stages of chronic kidney disease  
CKD                                                                                             GFR 
stage                            Description                                      ml/min/1.73 m2  
1           Kidney damage with normal or increased GFR                    ≥ 90 
2           Kidney damage with mild reduction of GFR                         60-89 
3           Moderate reduction of GFR                                                30-59 
4           Severe reduction of GFR                                                   15-29 
5           Kidney failure                                                            <15 or dialysis 
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2.2.3 Epidemiology and etiology of CKD 
Most epidemiological information on CKD originates from data available 
on ESRD; the terminal stage of CKD when treatment with renal replacement 
therapy (dialysis or transplantation) becomes necessary to sustain life. Little 
information is available on the prevalence of earlier stages of CKD, as patients 
are often asymptomatic (Warady and chadha, 2007). 
In the United States, kidney disease was the ninth leading cause of death 
in 2004 (Minino et al., 2004). The incidence of the ESRD in USA was 33.6 per 
100 000 population, this incidence has doubled over the past decade (Hamer 
and El Nahas, 2006). The National Health and Nutrition Examination Surveys 
(NHANES) in 1999-2004 estimates the prevalence of CKD stages as 1.8 % for 
stage one, 3.2 % for stage two, 7.7 % for stage three, and 0.35 % for stage 
four. The prevalence in all stages of CKD was higher than the prevalence of the 
survey in 1988-1994 (Coresh et al., 2007).  
In the United Kingdom, the annual incidence of ESRD is around 10 per 
100000 population, and it is expected to rise 5-8% annually. The European 
average is around 13.5 per 100000 population (Hamer and El Nahas, 2006).  
A study from the Kingdom of Saudi Arabia indicated an increase in the 
incidence of ESRD from 6.52 per 100000 population in the 1988 to 13.75 per 
100000 population in the 2001 (Mohamed et al., 2004). 
The Palestinian reports on the leading causes of death among population 
by age group and sex in Palestine showed that the incidence of renal failure 
was 10.8 per 100000 population, and the prevalence was 4%, distributed as 
1.1% in Gaza strip and 2.9% in the West Bank (MOH, 2005). 
The relation between CKD and gender is controversial; studies showed 
that the CKD is predominant in males than females (Lubasch et al., 1989; 
Kinchen et al., 2002 and Mohamed et al., 2004). In other studies, however, the 
prevalence of CKD was reported to be higher in females (Zhang and 
Rothenbacher, 2008). In general the highest incidence of CKD, especially 
ESRD, is elevated in the elderly people (Mohamed et al., 2004; Hamer and El 
Nahas, 2006). Regarding race, in the USA, ESRD rates in blacks are 2.7 times 
higher than in whites (Gulati, 2008). 
In adults, diabetes is the leading cause of kidney disease, 48.5% of renal 
failure is due to diabetes, 16.5% hypertension, 17.7% glomerulonephritis and 
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20.3% is due to other causes such as kidney inflammation, genetic diseases, 
autoimmune diseases, and birth defects (Kinchen et al., 2002). In children there 
is a wide range of conditions and causes of CKD such as: Intrauterine 
infections, drugs intake in early pregnancy, genetic kidney disease, congenital 
anomalies of kidney, postnatal infections, metabolic diseases, and nephrotoxic 
drugs (Vijayakumar et al., 2007). 
 
2.3 Cardiovascular disease in CKD patients 
Arterial vascular disease and cardiomyopathy are the primary types of 
CVD. In CKD, it is useful to consider two subtypes of arterial vascular disease, 
namely atherosclerosis and arteriosclerosis or large vessel remodeling (Table 
2.4) (Sarnak et al., 2003). 
 
Table 2.4 Spectrum of cardiovascular disease in chronic kidney disease 
Types of CVD Pathology  Clinical presentations of CVD  
 
Atherosclerosis 
IHD (myocardial infarction, angina, 
sudden cardiac death), 




disease Arteriosclerosis: Dilated 










HF, hypotension, IHD 
 
IMT: intima-media thickness, IHD: ischemic heart disease, HF: heart failure, LVH: left 
ventricular hypertrophy, PVD: peripheral vascular disease 
 
Atherosclerosis is an intimal disease characterized by the presence of 
plaques and occlusive lesions in the wall of blood vessels (London et al., 2002). 
There is a high prevalence of atherosclerosis in CKD. Atherosclerotic lesions in 
CKD are frequently calcified, and have increased media thickness in 
comparison with lesions in the general population (Schwarz et al., 2000).   
 
2.3.1 Epidemiology of CVD in CKD 
Cardiovascular disease is frequently associated with CKD, and CKD 
appears to be a risk factor for CVD. The National Kidney Foundation, American 
Heart Association, and the Seventh Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure have classified 
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the presence of chronic kidney disease as a cardiovascular risk factor (Shlipak 
et al., 2005). National Kidney Foundation Task Force on Cardiovascular 
Disease in Chronic Renal Disease issued a report which showed that there was 
a high prevalence of CVD in CKD and that mortality due to CVD was 10 to 30 
times higher in dialysis patients than in the general population. The task force 
recommended that patients with CKD be considered in the “highest risk group” 
for subsequent CVD events (Levey et al., 1998).  
Cardiovascular disease accounts for approximately half of deaths in 
ESRD. The incidence of myocardial infarction and stroke in the dialysis 
population is 5 to 15 fold higher in ESRD. This increased risk is only partially 
explained by a high prevalence of atherosclerotic cardiovascular disease 
(ASCVD) and traditional ASCVD risk factors at the initiation of dialysis 
(Longenecker et al., 2002). 
It was recognized that earlier stages of CKD also are a risk factor for CVD 
mortality (Flack et al., 1993; O’Brien et al., 2002). The risk for death from CVD 
was 1.8 times greater for persons with an estimated GFR of less than 70 
mL/min per 1.73 m2 than for those with a GFR of 90 mL/min per 1.73 m2 or 
more after adjustment for age, race, sex, systolic blood pressure (SBP), serum 
total cholesterol level, BMI, diabetes, family history of CVD, physical inactivity, 
and level of education (Muntner et al., 2002).  
The spectrum of CVD in children is different than in adults. In children, left 
ventricular hypertrophy and left ventricular dysfunction occurs more commonly 
in children with CKD compared to children without CKD. Congestive heart 
failure and arrhythmias are less common manifestation of CVD in children with 
CKD (Chavers and Herzog, 2004).   
 
2.3.2 Cardiovascular disease risk factors in CKD 
Cardiovascular disease risk factors are classified in CKD patients as either 
traditional or nontraditional (CKD specific) CVD risk factors (Table 2.5) (Sarnak 
and Levey, 2000). Traditional risk factors defined as those in the Framingham 
Heart Study that have been used to estimate the risk of developing 
symptomatic ischemic heart disease (Anderson et al., 1991; Wilson et al., 
1998). Most of the traditional CVD risk factors are highly prevalent in CKD 
(Sarnak et al., 2003). Several nontraditional factors are associated with 
Chapter 2                                                                                    Literature Review    
13 
atherosclerosis (Kronenberg, 1999; NKF, 2003). Other CKD specific CVD risk 
factors such as anemia are associated with cardiomyopathy (Levin et al., 1996; 
Levin et al., 1999), whereas abnormal calcium and phosphorus metabolism is 
associated with vascular remodeling and development of noncompliant vessels 
(Guerin et al., 2000).  
 
 
Table 2.5 Traditional and chronic kidney disease specific cardiovascular disease 
risk factors    




Higher LDL cholesterol 















Extracellular fluid volume overload 
Electrolyte imbalance 
Oxidative stress 




Altered nitric oxide/endothelin 
balance 
 
LDL indicates low-density lipoprotein; HDL: high-density lipoprotein; LVH: left ventricular 
     Hypertrophy. 
 
2.3.2.1 Hypertension 
Hypertension is one of the most common traditional cardiovascular risk 
factors that is highly prevalent in CKD (Sarnak et al., 2003). Chronic kidney 
disease associated hypertension develops by a large variety of 
pathophysiological mechanisms. While fluid overload and activation of the 
renin–angiotensin system have long been recognized as crucial 
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pathophysiological pathways, sympathetic hyperactivation, endothelial 
dysfunction and chronic hyperparathyroidism have more recently been 
identified as important factors contributing to CKD-associated hypertension 
(Hadtstein and Schaefer, 2008). 
The prevalence of CKD-associated hypertension varies between 30 % 
and 100 % depending on the target population, cause of renal disease, and 
level of renal function (Blankestijn, 2005). In children, hypertension is one of the 
most common sequelae of CKD (Wong et al., 2006), and blood pressure is one 
of the most critical determinants of the progression rate of renal failure in 
children (Wingen et al., 1997; Mitsnefes et al., 2003).  
  
2.3.2.2 Obesity and physical inactivity 
People with inactive lifestyles or who have too much body fat have 
increased risk of CVD (Food and Drug Administration, 2004). Obesity and 
physical inactivity were associated significantly with CKD (Stein et al., 2006). 
Obesity may be the number one preventable risk factor for CKD due to its 
strong link with diabetes and hypertension, the two primary causes of CKD and 
kidney failure in adults (Kramer, 2006). 
 
2.3.2.3 Dyslipidemia 
Dyslipidemia is any abnormality in plasma lipoprotein concentration or 
composition that is associated with an increased risk for atherosclerotic 
cardiovascular disease (ACVD) (NKF, 2003). Dyslipidemia has been 
established as a well-known traditional risk factor for CVD in the general 
population and large-scale observational studies have shown that total 
cholesterol and low density lipoprotein (LDL) values are two of the most 
important independent predictors of cardiovascular morbidity and mortality 
(Lewington et al., 2007). Also, it is well known that patients with impaired renal 
function exhibit significant alterations in lipoprotein metabolism. Although lipid 
abnormalities were originally considered as complications of ESRD, these 
changes can be present in early stages of CKD and may actively participate in 
the pathogenesis of serious complications such as ACVD (Tsimihodimos et al., 
2008). The most common quantitative lipid abnormalities in predialysis CKD 
patients are hypertriglyceridemia, increased concentrations of triglyceride-rich 
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lipoprotein remnants, reduced high density lipoprotein (HDL) levels as well as 
increased concentrations of lipoprotein(a) (Vaziri and Moradi , 2006). 
 
2.3.2.4 Albuminuria 
Albuminuria is defined as ″UAE over 30 mg/day, if measured in a 24 h 
urine collection or over 30 mg/g, if measured with the use of urinary ACR in a 
spot urine collection″. Urinary albumin excretion between 30 and 300 mg/day, 
or 30-300 mg/g is defined as microalbuminuria, any urinary albumin value 
below these limits is considered as normal UAE, whereas any value above 
them reflects the presence of macroalbuminuria or clinical proteinuria 
(American Diabetes Association, 2004; Kidney Disease Outcomes Quality 
Initiative, 2004). It has long been noted that subclinical elevations of UAE are 
related to higher risk of subsequent development of clinical nephropathy in 
patients with diabetes mellitus (Viberti et al., 1982; Mogensen, 1984), and that 
increased UAE was associated with higher risk for CV events and mortality in 
both diabetic and non-diabetic individuals (Mogensen, 1984; Stehouwer et al., 
1992). Prolonged protein loss leads to hypoalbuminemia, hyperlipidemia and 
coagulation abnormalities following hyperfibrogenemia, increase in Factor III 
and Von Willebrand factor. Microalbuminuria occurring in early diabetic 
nephropathy is a marker of vascular endothelial dysfunction (Amaresan, 2005).  
 
2.3.2.5 Anemia  
Anemia is defined as a low red blood cell count. Since the red blood cells 
contain hemoglobin, we simply measure its concentration. In children, KDOQI 
defined anemia as hemoglobin less than 11 g/dl (Feber and Wong, 2007). The 
kidney being the main source of erythropoietin, anemia is apparently an integral 
part of advancing renal failure. Anemia exerts an independent effect on CVD in 
CKD. For every 1g/dl drop in mean hemoglobin , the risk of cardiac failure (de 
novo) increases by 25% and risk of death increases by 14% ( Metivier, 2000). 
Depression of red cell production is the consequence of decreased renal 
production of the hormone erythropoietin. Increased red blood cell destruction 
resulting from uremic toxins as well as the mechanical damage to red cell 
observed in a variety of glomerular disease (Kissane, 1990). The 
pathophysiology of CVD induced by anemia is illustrated in Figure 2.3.  





Figure 2.3. Adverse cardiovascular effects of anemia 
 
2.3.2.6 Calcium/phosphorus metabolism 
In humans with CKD, there appears to be a relationship between 
disorders of mineral metabolism (abnormal levels of serum calcium and 
phosphorus), abnormal bone (renal osteodystrophy), and vascular calcification 
(Moe and Chen, 2004). Progressive nephron loss is associated with phosphate 
retention and hypocalcemia early in the disease, but then can develop 
hypercalcemia when given calcium or vitamin D (Moe and Drueke, 2003). This 
triggers increased parathyroid hormone (PTH) activity. The secondary 
hyperparathyroidism along with hyperphosphatemia and increased calcium 
phosphate ion product are identified as independent cardiovascular risk factors 
(Brancaccio et al., 2002). Secondary hyperparathyroidism results in impaired 
calcitrol synthesis, increased skeletal resistance to PTH, increased parathyroid 
cell hyperplasia, and decreased expression of calcium sensing receptors. 
These end in decreased cardiac contraction, LVH and valvular calcification 
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(Amaresan, 2005). There is 2- to 5-fold increase in coronary artery calcification 
in dialysis patients compared with age-matched non-CKD patients with 
angiographically proven coronary artery disease (Braun, 1996). The goal level 
of Ca X P should be below 55 mg2/dl2 in adolescents, and below 65 mg2/dl2 in 
infants and children, due to the normal higher serum phosphorus level in the 
latter groups (NKF, 2005). 
 
2.3.2.7 C-reactive protein 
In the general population, elevated levels of C-reactive protein (CRP) have 
been associated with an increased risk for cardiovascular disease (Stampfer et 
al., 1992; Danesh et al., 2000). Besides a risk marker, there is increasing 
evidence that CRP may be directly involved in thrombogenesis. C-reactive 
protein present in the vessel wall induces expression of adhesion molecules by 
endothelial cells which serves as a chemoattractant for monocytes. It opsonises 
LDL and facilitates native LDL entry into macrophages. C-reactive protein binds 
to plasma membrane of damaged cells and activates complement via the 
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 2.4 Related studies  
Locatelli et al. (2003) analyzed the prevalence of the major CVD risk 
factors in CKD patients and their importance as contributors to the excess CVD 
in their study population. They found out that hypertension plays a major role in 
determining cardiac damage at all stages of CKD, including the dialytic phase. 
They also reported that anemia was a major determinant of the development of 
LVH and therefore its correction can be expected to improve cardiovascular 
status and long-term survival, but this needs to be done before changes in 
cardiac structure become well established. The study also showed that 
calcium–phosphate disorders were important cardiovascular risk factors in 
CKD, and that dyslipidaemia was particularly frequent in CKD patients. 
 
In a study that comprised 369 individuals with CKD not receiving renal 
replacement therapy at baseline assessment, the patients were compared with  
two age- and sex-matched control groups, one comprising 103 patients with 
angiographically-proven coronary artery disease and the other 103 apparently 
healthy individuals. Of the patients with kidney disease, 34% had vascular 
disease and 21% LVH according to electrocardiographic criteria. The study 
indicated that the traditional risk factors included history of hypertension in 
76%, diabetes in 15% and dyslipidaemia with reduced LDL cholesterol, 
elevated triglyceride and decreased HDL cholesterol levels. Other possible risk 
factors included elevated levels of plasma homocysteine, a low serum albumin, 
an elevated CRP and a low haematocrit (Wheeler et al., 2003).  
 
Goicoechea et al. (2005) studied a 128 (78 males, 50 females) of CKD 
patients with estimated GFR <60 mL/min. The patients were prospectively 
followed. After a mean follow-up of 22.3 months, 27 patients had a 
cardiovascular event. The patients who suffered a cardiovascular event were 
older (p= 0.002), with more anemia (p= 0.014), higher pulse pressure (p= 
0.011). In addition, they had more prevalence of LVH (p= 0.001) and diabetes 
(p= 0.013). 
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Litwin et al. (2005) in their study on young patients with onset CKD, they 
categorized the patients into 3 groups, stage 2-4 CKD, dialysis patients, and 
renal transplantation. Compared with control all patient groups were 
significantly smaller and lighter and had higher blood pressure and 
triglycerides. Patients on dialysis and after renal transplantation had higher total 
cholesterol, whereas LDL was selectively increased in the dialysis group. 
Phosphorus, Ca x P product and PTH levels were higher in the dialysis than in 
the CKD and post- renal transplantation group. 
 
Zhang et al. (2006) in their study on a Chinese population of individuals 
who were older than 40 years found that, the prevalence of CVD was markedly 
increased in early stages of CKD. Compared with participants with GFR >90 
ml/min per m2, participants in stage 2 and 3 of CKD tended to have more 
cardiovascular risk factors such as older age, obesity, diabetes, hypertension, 
hypercholesteremia, and albuminuria.  
 
Parikh et al. (2006) assessed the comparison of the prevalence of CVD 
risk factors and their control and treatment among persons with and without 
CKD in 3258 subjects with mean age of 60±9 year. They concluded that              
those with CKD were older, more likely to be obese, and more likely to have 
low levels of HDL cholesterol, and high triglyceride levels. Those with CKD had 
a higher prevalence of hypertension. Participants with CKD had a higher 
prevalence of elevated LDL cholesterol levels (60.5% vs. 44.7%; p=.06) and 
lipid-lowering therapy (57.1% vs. 42.6%; P=.09), although this was not 
statistically significant. A greater proportion of individuals with CKD had 
diabetes than those without. 
The association between CKD stages 3 and 5, and alterations of calcium, 
phosphate, vitamin D and PTH concentrations were assessed in 249 patients 
(mean age 61 years, 66% male) and 79 age- and sex-matched healthy controls 
(Zehnder et al., 2007). As compared to controls, serum phosphate 
concentrations were elevated among CKD patients (1.40 vs. 1.11 mmol/l; p < 
0.0001). Levels of both 25-hydroxyvitamin D (42.1 vs. 60.4 nmol/l; p < 0.0001) 
and 1,25-dihydroxyvitamin D (58.2 vs. 119.5 pmol/l; p < 0.0001) were lower 
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among patients with CKD. Concomitant elevations were observed in intact PTH 
(13.8 vs. 4.2 pmol/l; p < 0.0001) and whole PTH (7.9 vs. 2.7 pmol/l; p < 
0.0001).  
Essig et al. (2007) in their study on 104 patients with early CKD (mean 
GFR 60±21 ml/min/1.72 m2) aged 18 to 75 years, biochemical analysis and 
ultrasound studies were conducted for the patients to determine the 
cardiovascular remodelling and extracellular fluid excess in early stages of 
CKD. Results showed that 71 patients were males and 33 were females. 
Eleven patients were stage-1 CKD, 36 stage-2, and 57 stage-3. There was a 
significant increase in homocystein, PTH, and SBP across the three CKD 
stages. The results of ultrasound showed that there was an association 
between GFR decline and LVH in 58% of stage-1 and 68% of stage-2. 
Glomerular filtration rate decrease was also associated with common carotid 
remodeling and increased aorta stiffness. 
 
Levin (2008) reported that the increase in CVD burden is present in 
patients prior to dialysis, due to both conventional risk factors as well as those 
specific to kidney disease. Of importance is that even in patients with mild 
kidney disease, the risk of cardiovascular events and death was increased 
relative to patients without evidence of kidney disease. The prevalence of 
hypertension was high in patients with CKD (87–90%). At least 35% of patients 
with CKD had evidence of an ischemic event (myocardial infarction or angina) 
at the time of presentation to a nephrologist. The prevalence of LVH increased 
at each stage of CKD, reaching 75% at the time of dialysis initiation, and the 
modifiable risk factors for LVH including anemia and SBP were also worsen at 
each stage of kidney disease. Even under the care of nephrologists, a change 
in cardiac status (worsening of heart failure or anginal symptoms) occurred in 
20% of patients. 
 
Abo-shamala (2008) investigated PTH, calcium and phosphorus levels in 
80 hemodialysis patients who have been on hemodialysis for ≥ 12 month at al-
shifa hospital, Gaza- Palestine. He reported that there were statistically 
significant differences in the mean levels of serum PTH, Ca x P product, 
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albumin, phosphorus and ionized calcium between the patients and controls. 
The results were as the follows: (PTH: 1715±1706.3 vs. 35.7±14.7 pg/ml), (Ca 
x P product: 62.7±14.6 vs. 40.2±6.0 mg2/dl2), (albumin: 4.6±0.39 vs. 4.7±0.3 
g/dl), (P: 6.6±1.4 vs. 4.3±0.6 mg/dl), and (ionized calcium: 3.78±0.47 vs. 
4.7±0.1 mg/dl). 
 
The burden of CVD in children with CKD (by measurement of cardiac and 
vascular changes and risk factors for the development of CVD)  was discussed   
by Shroff (2009). He reported that LVH was developed early in the course of 
renal decline and it was widely prevalent in children on dialysis with 85% of 
hemodialysis and 65% of peritoneal patients having eccentric LVH. Progression 
of LVH was associated with anemia, hyperparathyroidism and systolic 
hypertension. Carotid artery intima media thickness was showing that children 
on dialysis had higher carotid artery intima media thickness than pre-dialysis 
CKD or transplant patients. These vascular changes were initiated as early as 
the first decade of life in children on dialysis
 
and were also present in pre-
dialysis CKD stages II – IV. Chronic kidney disease patients had a higher 
prevalence of both the traditional risk factors (such as dyslipidemia, 
hypertension, diabetes, smoking and physical inactivity) as well as non-
traditional risk factors that were both disease-related (e.g. dysregulated mineral 
metabolism, anemia, hypertension and fluid overload, inflammation and 
oxidative stress) and potentially treatment-related (e.g. calcium overload from 




























3.1 Study design 
 The present study is a cross sectional study, that was conducted from 
the beginning of December, 2008 to the end of March, 2009. 
 
3.2 Setting of the study 
The study was carried out at the Nephrology Department of Abd El-Aziz 
El-Rantisy specialized pediatric hospital. Experimental work was performed at 
the laboratory of the Public Aid Hospital in Gaza. 
 
3.3 Study population 
Patients from both genders who had renal disease and registered in the 
Nephrology Department of the hospital. The total number of cases in the 
department was 305 patients at the end of the study. 
 
3.4 Study sample  
Study sample comprised 112 subjects divided as 60 CKD patients and 
52 healthy individuals as a control group.  The control group was 
normotensive,   non diabetic children with no history of renal or cardiovascular 
disease. Control and patients were ≤ 12 years old. 
 
3.5 Selection criteria 
3.5.1 The inclusion criteria  
• Patients with age ≤ 12 years old.  
• Diagnosed as CKD patients. 
3.5.2 The exclusion criteria  
• Patients with kidney replacement therapy (hemodialysis, peritoneal 
dialysis or kidney transplantation). 
• Clinically overt inflammatory disease at the time of investigation. 
• Clinically significant overhydration or dehydration. 








3.6 Ethical considerations 
1- Helsinky committee approval was obtained (Appendix 2).  
2- Coordination with the Ministry of Health was fulfilled (Appendix 3). 
3- Parents of the participants were given a full explanation about the 
purpose of the study, assurance about the confidentiality of the 
information obtained through the questionnaire and blood analysis, and 
that they have the right to refuse to participate or to drop out in any 
phase of the study. 
 
3.7 Data Collection 
Data were collected by both direct and indirect methods.  
3.7.1 The direct method  
Laboratory investigations including blood sampling after 12-14 hour 
overnight fasting and the following blood tests were done for patients and 
controls: Creatinine, urea, albumin, cholesterol, triglycerides, HDL, LDL, 
phosphorus, calcium, hemoglobin, glucose, CRP. Additionally, spot urine 
samples were tested for ACR. Glomerular filtration rate was estimated in all 
participating subjects according to the Schwartz formula (Table 2.1). Height, 
weight, blood pressure were measured for each participant. Body mass index 
was also calculated for all subjects.    
3.7.2 The indirect method 
Face to face interview questionnaire was administrated for both patients 
and controls (Appendix 1), 
The questionnaire main content included: 
1- Personal data. 
2- History of the disease (for patients) 
3- Physical activity 
4- History of CVD in the patients, family 
 
3.8 Data entry and statistical analyses  
Data entry and statistical analyses were performed using SPSS 
(Statistical Package for Social Sciences) software package version 11. The 
variables were analyzed using descriptive statistics, independent samples t-




test, and one-way ANOVA test. Results were expressed as frequency or 




3.9.1 Chemicals and reagents 
Chemicals and reagents used in this study are shown in Table 3.1. 
 
Table 3.1 Chemicals and reagents used in the present study. 
Reagent Supplier 









CRP                                                   
Total calcium 
 CBC                                                   
Quality control: 
Nova 10 electrolytes controls 
multi-control sera 
R and D, CBC controls 
CRP positive control 
CRP negative control 
Diasys Diagnostic Systems, Germany 
Diasys Diagnostic Systems, Germany 
Diasys Diagnostic Systems, Germany 
BioSystems, Spain 
Diasys Diagnostic Systems, Germany 
Diasys Diagnostic Systems, Germany 
Diasys Diagnostic Systems, Germany 
Diasys Diagnostic Systems, Germany 
Diasys Diagnostic Systems, Germany 
Labkit, Chemelex, Spain 
Nova Biomedical, USA 
Abbott, USA 
 
Nova Biomedical, USA 
Human, Germany 
R and D systems, USA 
Labkit, Chemelex, Spain 













The main equipment that were used are listed in Table 3.2. 
 











Stat Fax-1904 Plus, Awareness Technology Inc. 
USA  
Nova 10, Nova Biomedical, USA 









3.10.1 Sampling and processing 
Blood samples were collected from patients and controls who agreed to 
participate in the study after overnight 12- 14 hr fasting. Five ml blood were 
obtained from each subject and divided into EDTA tube (1.0 ml) and 
vacutainer plain tube (4.0 ml). Vacutainer plain tubes were left for short time 
to allow blood to clot, then clear serum samples were obtained by 
centrifugation at 4000 rpm for 10 minutes. A spot sample of morning urine in 
the fasting state was collected from each subject. Urine albumin, urine 
creatinine and CBC were done in the same day of collection. Serum samples 
were stored at -20 ºC until the time of performing the analysis. All biochemical 
analyses were done in the laboratory of the Public Aid Hospital in Gaza. 
 
3.10.2 Height, weight, BMI and blood pressure measurements 
Height was measured to the nearest 1.0 cm and weight to the nearest 
0.1 kg. Blood pressure was measured in the right arm, with the subject in a 
relaxed, sitting position. The average of two measurements with a mercury 
sphygmomanometer was used in all subjects. 





3.10.3 Calculated measurements  
• Glomerular filtration rate was calculated by Schwartz equation: 
GFR (ml/min/1.73m2) = 0.55x length / serum creatinine 
• Albumin/creatinine ratio  
ACR (mg/g) = Microalbumin in urine (mg/L) x1000 /creatinine in urine              
(mg/dl) x10 
the urine creatinine value is multiply by 10 to convert mg/dL to mg/L, 
then divide the urine albumin value by the urine creatinine value to 
arrive at the ratio, then multiply by 1000 to express the value as (mg 
albumin/g creatinine). 
• Low density lipoprotein was calculated by Friedewald equation: 
LDL (mg/dl) = cholesterol – (HDL + triglycerides/5)) 
• Body-mass index  
      BMI = the weight in kilograms / square of the height in meters 
• Calcium x Phosphorus product 
Ca x P (mg2/dl2) = serum Ca (mg/dl) x serum P (mg/dl)  
 
3.10.4 Biochemical analyses 
Serum urea, creatinine, albumin, cholesterol, triglycerides, HDL, 
phosphorus, glucose, urine albumin, and urine creatinine were analyzed 
manually using Stat Fax-1904 plus spectrophotometer (Awareness 
Technology Inc. USA). Two levels of lyophilized multi-control sera (Human, 
Germany); normal and abnormal levels were analyzed with each run. The 
concentration of LDL was calculated from the results of a profile including 
total cholesterol, HDL and triglycerides using the Friedewald equation (LDL = 
cholesterol – (HDL + triglycerides/5)) (Kaplan and Szabo, 1983). Serum total 
calcium was analyzed using ion selective electrode by Nova 10 electrolyte 
analyzer, Nova Biomedical, USA. Four levels of controls: I, II, III, IV were 
analyzed with each run. C-reactive protein was analyzed using semi-
quantitative latex method; positive and negative controls were used in each 
run. Complete blood count was measured using Cell-DYN 1800 cell counter, 




Abbott, USA. Three controls (R and D systems, USA), high, normal, and low 
were used in each run of CBC.  
 
 
3.10.4.1 Determination of serum urea  
 
Method 
Urease- Glutamate dehydrogenase (GLDH): enzymatic UV test 
 
Principle 
Urea + 2H2O    → 2NH4 + 2HCO 
2-Oxoglutarate + NH4 + NADH   → L-Glutamate + NAD+ + H2O 
 
Reagents 





≥ 0.6 ku/l 






0.25 mmol/l R2: NADH 




The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 340 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against distilled water. 
Urease 
GLDH




• 10 µl of standard (sample or control) was added to 1 ml of working 
reagent and mixed well. 
• The mixture was incubated for 30 sec then absorbance (A1) was 
recorded. 
• After exactly further 60 sec the absorbance (A2) was measured. 
 
Calculation 
∆A = (A1 –A2) sample or standard 




Reference value  
(Palestinian clinical laboratory tests guide, PCLTG, 2005) 
Child 5 - 30 mg/dl 
Adult 13 - 43 mg/dl 
 
3.10.4.2 Determination of serum creatinine  
 
Method 
Kinetic test without deproteinization according to the Jaffe method. 
 
Principle 
Creatinine forms a colored orange-red complex in an alkaline picrate solution. 
The difference in absorbance at fixed times during conversion is proportional 
to the concentration of creatinine in the sample. 
Creatinine + Picric acid → creatinine picrate complex 
Reagents 
Concentrations are those in the final test mixture. 
Concentration Reagent 
0.16 mol/l R1: Sodume hydroxide (pH approx. 13) 
4.0 mmol/l R2: Picric acid (pH approx. 1.2) 
2.0 mg/dl Standard 









The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 490 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement:  against distilled water. 
• 50 µl of standard (sample or control) was added to 1 ml of working 
reagent add and mixed well. 
• The Mixture was incubated for 60 sec then absorbance (A1) was 
recorded. 
• After exactly further 120 sec the absorbance (A2) was measured. 
 
Calculation 
∆A = (A1 –A2) sample or standard 
Creatinine (mg/dl) = ∆A sample X concentration of standard 
Note: Creatinine in urine was analyzed by the same procedure for serum 
creatinine after diluting urine 1+ 49 of distilled water and the result was 
multiplied by 50.   
Reference value (in serum) (PCLTG, 2005) 
Infant 0.2 – 0.4 mg/dl 
Child 0.3 - 0.7 mg/dl 
Adolescent 0.5 - 1.0 mg/dl 
Adult:  M 
F 
0.6 - 1.2 mg/dl 
0.5 -1.1 mg/dl 
 
   
3.10.4.3 Determination of serum albumin 
 
Method 
Photometric test using bromocresol green. 
 
Principle 
Serum albumin in the presence of bromocresol green at a slightly acid pH 
produces a color change of the indicator from yellow-green to green blue.      
 
∆A stand rd 








Citrate buffer (pH 4.2) 
Bromocresol green    
5 g/dl Standard 
                                
Assay procedure 
Wavelength: 546 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement:  against reagent blank. 
• 10 µl of standard (sample or control) was added to 1 ml of working 
reagent and mixed well. 
• The mixture was incubated for 10 min at 37 ºC.  
• The absorbance was measured within 60 min. 
Calculation 
Albumin (g/dl) = ∆A sample X concentration of standard 
 
 
Reference value (PCLTG, 2005) 
3.8 – 5.4 g/dl Child 
3.2 – 4.5 g/dl Adolescent 
3.4 – 4.8 g/dl Adult 
 
 
3.10.4.4 Determination of urine albumin 
 
Method 
Latex agglutination test. 
 
Principle 
Albumin in the urine sample causes agglutination of the latex particles coated 
with anti-human albumin. The agglutination of the particles is proportional to 
the albumin concentration and can be measured by turbidimetry. 
 
∆A standard 








Reagent A: Borate buffer 




Reagent B: Suspension of latex particles 
coated with anti-human albumin antibodies 
                    Sodium azide 
46.9 mg/L Albumin standard 
 
Assay procedure 
The working solution was prepared by mixing 4 parts of R1 with 1 part of R2.  
Wavelength: 540 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against distilled water 
• 7 µl of standard (sample or control) was added to 1 ml of working 
reagent and mixed well. 
• The Mixture was incubated for 10 sec then absorbance (A1) was 
recorded. 
• After exactly further 120 sec the absorbance (A2) was measured. 
 
Calculation 
∆A = (A2 –A1) sample or standard 
Albumin in urine (mg/L) = ∆A sample X concentration of standard 
 
 
Albuminuria was calculated by albumin/creatinine ratio in spot urine samples 
as shown in calculated measurements 
 
Albumin/Creatinine Ratio Results (Sarafidis and Bakris, 2006) 
Condition Value 
Normal < 30 mg/g 
Microalbuminuria 30-300 mg/g 








3.10.4.5 Determination of serum cholesterol  
 
Method 
Enzymatic photometric test 
 
Principle 
Determination of cholesterol after enzymatic hydrolysis and oxidation. The 
colorimetric indicator is quinoneimine which is generated from 4-




Cholesterol ester + H2O   →   cholesterol + fatty acid 
 
 
Cholesterol + O2      →   cholesterol-3-one + H2O2 
 
 









≥ 200 u/l 
≥ 100 u/l 
≥ 3 ku/l 
Good,s buffer (pH 6.7)   
Phenol 
4- Aminoantipyrine 
Cholesterol esterase (CHE) 
Cholesterol oxidase (CHO) 
Peroxidase (POD) 
200 mg/dl                Standard 
 
Assay procedure 
Wavelength: 500 nm 
Optical path: 1cm 
Temperature: 37 ºC 








• 10 µl of standard (sample or control) was added to 1 ml of working 
reagent and mixed well. 
• The mixture was incubated for 5 min at 37 ºC.  
• The absorbance was measured within 60 min. 
 
Calculation 
Cholesterol (mg/dl) = ∆A sample X concentration of standard 
 
 
Reference value (PCLTG, 2005) 
Child (desirable)     < 170 mg/dl 
Adult (desirable)    <200 mg/dl 
 
Levels in term of risk for coronary heart disease 
Adults Children  
200 -239 mg/dl 170-199 mg/dl Critical value risk 
≥ 240 mg/dl ≥ 200 mg/dl High risk 
 
 
3.10.4.6 Determination of serum triglycerides 
 
Method  
Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO) 
 
Principle 
Determination of triglycerides after enzymatic splitting with lipoprotein lipase. 
Indicator is quinoneimine which is generated from 4-aminoantipyrine and 4-
chlorophenol by hydrogen peroxide under the catalytic action of peroxidase.  
 
Triglycerides     →  Glycerol + fatty acid  
 
Glycerol + ATP      →  Glycerol-3-phosphate + ADP  
 
Glycerol-3-phosphate    + O2  →   Dihydroxyaceton  phosphate + H2 O2  
 












Concentrations are those in the final test mixture. 
Reagent Concentration 




Glycerokinase   (GK)   
Peroxidase    (POD) 
Lipoprotein lipase   (LPL) 
4-Aminoantipyrine 
Glycerol-3-phosphate-oxidase (GPO) 
50  mmol/l 
4   mmol/l 
2   mmol/l 
15 mmol/l 
≥ 0.4 KU/I 
≥  2  KU/I 
≥  2  KU/I 
0.5 mmol/l 
≥ 0.5 KU/I 
Standard 200 mg/dl 
 
Assay Procedure  
Wavelength:   500 nm 
Optical path:  1 cm   
Temperature: 37 ºC 
Measurement: Against reagent blank. 
• 10 µl of standard (sample or control) was added to 1 ml of working 
reagent and mixed well. 
• The mixture was incubated for 5 min at 37 ºC.  




Triglycerides [mg / dl] = ∆A sample X concentration of standard 
 
 
Reference value (PCLTG, 2005) 
30 - 150 mg/dl Child (desirable) 
40 - 160 mg/dl 
35  - 135 mg/dl 
Adult (desirable)    M 
                               F    








3.10.4.7 Determination of serum HDL 
 
Method 
Precipitation of LDL, very low density lipoprotein (VLDL) and chylomicrons. 
 
Principle 
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic 
acid and magnesium ions to the sample. Centrifugation leaves only the HDL 






8.6 mmol/l    
Monoreagent contain: Magnesium chloride 
                                    Phosphotungstic acid 
               
200 mg/dl     Choesterol standard 
 
Assay procedure  
1- Precipitation  
• 200 µl of standard (sample or control) was added to 500 µl of the 
precipitation reagent and mixed well. 
• The mixture was allowed to stand for 15 min at room temperature, and 
then centrifuged for 20 min at 4000 rpm.  
2- Cholesterol determination 
Wavelength: 500 nm 
Optical path: 1cm 
Temperature: 37 ºC 
Measurement: against reagent blank. 
• 100 µl of the supernatant of standard (sample or control) was added to 
1 ml of the cholesterol reagent and mixed well. 
• The mixture was incubated for 5 min at 37 ºC.  
• The absorbance was measured within 45 min.  
 
 





HDL-C (mg/dl) = ∆A sample X concentration of standard 
 
 







3.10.4.8 Determination of serum phosphorus 
 
Method 
Photometric UV test. 
 
Principle 
Ammonium molybdate + Sulphuric acid + Phosphate → inorganic phosphorus 
molybdate complex. 






Sulphuric acid    
Ammonium molybdate 
5 mg/dl Standard      
 
Assay Procedure  
Wavelength:  340 nm 
Optical path:  1 cm   
Temperature: 37 ºC 
Measurement: Against reagent blank. 
• 10 µl of standard (sample or control) was added to 1 ml of the reagent 
and mixed well. 
• The mixture was incubated for 5 min at 37 ºC.  
• The absorbance was measured within 60 min. 
37 – 75 mg/dl Child 
35 – 65 mg/dl 
35 – 80 mg/dl 
Adult: M 
           F                                
≤  35 mg/dl High risk of CHD 
∆A standard 





Phosphorus (mg/dl) = ∆A sample X concentration of standard 
 
 
Reference value (PCLTG, 2005) 
3.8 – 5.5 mg/dl 1 - 3 years 
2.9 – 5.4 mg/dl 4 - 15 years 




3.10.4.9 Determination of serum glucose 
 
Method  
Glucose oxidase (GOD), enzymatic photometric test. 
 
Principle 
Determination of glucose after enzymatic oxidation by glucose oxidase. The 
colorimetric indicator is quinoneimine, which is generated from 4-
aminoantipyrine and phenol by hydrogen peroxide under the catalytic action 
of peroxidase. 
 
Glucose + O2  → Gluconic acid + H2O2 
 
 
    




























≥ 15 ku/l 
≥ 1 ku/l 
Phosphate buffer (pH 7.5) 
Phenol   
4-Aminoantipyrine 
Glucose oxidase (GOD) 
Peroxidase (POD)   
100 mg/dl Standard 
 
Assay procedure 
Wavelength:   500 nm 
Optical path:  1 cm   
Temperature: 37 ºC 
Measurement: Against reagent blank. 
• 10 µl of standard (sample or control) was added to 1 ml of the reagent 
and mixed well. 
• The mixture was incubated for 10 min at 37 ºC.  
• The absorbance was measured within 60 min.  
 
Calculation 




Reference value (fasting glucose) (PCLTG, 2005)   
60 – 100 mg/dl Child 














3.10.4.10 Determination of serum C-reactive protein 
 
Method 
Semi-quantitative latex method. 
 
Principle 
Semi-quantitative detection of CRP in human serum. Latex particles coated 




Latex: Latex particles coated with goat IgG anti-human CRP, pH 8.2. Sodium 
azide 0.95 g/L. 
Control (+): Human serum with CRP > 20 mg/L. Sodium azide 0.95 g/L. 
Control (-): Animal serum. Sodium azide 0.95 g/L. 
 
Assay procedure 
Qualitative method  
1. Reagent and samples wear allowed reaching to room temperature. 
2. 50 µl of the sample (positive and negative control) was placed into 
separate circle on the slide test. 
3. CRP-latex reagent was shacked gently and a drop was added next to 
the sample (positive and negative control). 
4. Both drops wear mixed and spreade over the entire surface of the 
circle.  
5. The slide was rotated with a mechanical rotator at 80-100 r.p.m. for 2 
minutes. 
Semi-quantitative method 
1. Serial two fold dilutions of the sample in 9.0 g/L saline solution wear 
made. 









Reading and interpretation 
The presence or absence of visible agglutination was examined 
macroscopically immediately after removing the slide from the rotator. The 
presence of agglutination was indicating CRP concentration equal or greater 
than 6 mg/L. 
The titer, in semi-quantitative method, was defined as the highest dilution 
showing a positive result. 
 
Calculations 
The approximate CRP concentration in the patient sample was calculated as 
follow: 6 x CRP titer = mg/L 
 
Reference values 
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4.1 Characteristics of the study population 
The present study is a cross sectional study, that included 112 children 
(60 patients and 52 controls).  
 4.1.1 Socio-demographic characteristics of the study population 
 The distribution of the study population by gender showed that males 
represented 40 (66.7%) of the patients and 28 (53.8%) of the controls whereas 
females represented 20 (33.3%) of the patients and 24 (46.2%) of the controls 
















Figure 4.1 Distribution of the study population by gender 
 
The age of the study population was divided into three main age groups 
(Figure 4.2). The age group 1-4 years represented 12 (20%) of the patients and 
11 (21.2%) of the controls. Twenty (33.3%) patients and 22 (42.3%) controls 
belonged to the age group 5-8 years. Age group 9-12 years consisted of 28 
(46.7%) patients and 19 (36.5%) controls. The age under one year was not 
present in the study sample. 
%














9-12 years5-8 years1-4 years
controls patients
 
Figure 4.2 Distribution of the study population by age 
 
Distribution of the study population by governorates is shown in Figure 
4.3. The majority of individuals were from Gaza [24 (40%) patients and 31 
(59.6%) controls]. The number of subjects from the North region were 18 (30%) 
patients and 11 (21.2%) controls, while 18 (30%) patients and 10 (19.2%) 
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The education level of the participants was categorized into three groups, 
illiterate (less than one year of education), 1-3 years of education, and 4-6 
years of education. Figure 4.4 illustrates the percentage of each group from 
both patients and controls.  The illiterate group was the most frequent; 29 
(48.3%) of patients and 22 (42.3%) of controls. The level of 1-3 years of 
education represented 15 (25%) of patients and 15 (28.8%) of controls. sixteen 
(26.7%) of patients and 15 (28.8%) of controls belonged to the level 4-6 years 
















Figure 4.4. Distribution of the study population with respect to educational level 
 
 
4.1.2 Height, weight and blood pressure of patients and controls  
 
Table 4.1 shows the mean values of height, weight, systolic and diastolic 
blood pressure in patients and controls. There were significant decreases in 
mean values of height and weight of patients as compared to controls 
(104.7±21.2 vs. 121.3±20.0 cm and 18.9±9.2 vs. 26.2±10.2 kg, respectively, 
p=0,000). In contrast there were significant increases in the systolic and 
diastolic blood pressure in the patients as compared to the controls (111.4±18.5 








Table 4.1 Means of height, weight, systolic and diastolic blood pressure in 
patients and controls  
 
Patients (n=60) Controls (n=52) 
Variable 
Mean ±SD Mean ±SD  
t p-value 
Height (cm) 104.7± 21.2 121.3 ± 20.0 -4.24 0.000 
Weight (kg) 18.9 ± 9.2 26.2 ±10.2 -3.98 0.000 
SBP (mmHg) 111.4 ±18.5 98.6 ±7.6 4.69 0.000 
DBP (mmHg) 70.3 ±17.6 63.9 ±5.6 2.5 0.014 
SBP: Systolic blood pressure, DBP: Diastolic blood pressure 
 
4.2 Kidney investigations and CKD classification  
All the participants were tested for the function of the kidney. Glomerular 
filtration rate was determined from serum creatinine and subjects height 
according to Schwartz formula (Table 2.2). Albumin/creatinine ratio was 
determined from spot urine sample to indicate the damage of the kidney and 
used as a marker of CVD event. Glomerular filtration rate and ACR were used 
in defining and classifying CKD.  
Table 4.2 illustrates the comparison of the mean values for urea, 
creatinine, ACR and GFR between patients and controls. The results showed 
significant difference between patients and controls in the mean values of urea 
(130.0±26.0 vs. 22.0±8.0 mg/dl, p=0.000). The mean values of creatinine were 
higher in patients than controls (2.57±1.51 vs. 0.47±0.11 mg/dl) with statistically 
significant difference (p=0.000). Albumin/creatinine ratio also showed 
significantly higher mean values in the patients as compared to the controls 
(1792±3183 vs. 11±6.0 mg/g, p=0.000). The wide variations in ACR values 
between patients and presence of some irregular values were the cause of 
large SD of the mean (SD=3183 mg/g), since the ACR values depend on the 
type of kidney disease. Regarding GFR, the results revealed that patients had 
significant reduction in GFR than controls (30.9±18.4 vs. 146.7±20.9 
ml/min/1.73m2, p=0.000).   
 





Table 4.2 Kidney investigations in patients and controls 
 
Kidney function tests Mean ±SD t p-value 
patient (n=60) 130.0 ± 62.0 
Urea  (mg/dl) 
control (n=52) 22.0 ± 8.0 
12.46 0.000 
patient (n=60) 2.57 ± 1.51 
Creatinine (mg/dl) 
control (n=52) 0.47 ± 0.11 
10.05 0.000 
patient (n=48) 1792 ± 3183  
ACR (mg/g) 
control (n=52) 11.0 ± 6.0 
4.04 0.000 
patient (n=60) 30.9 ± 18.4 GFR 




The patients were classified into 1 to 5 stages according to the NKF- 
KDOQI (Table 2.3). Figure 4.5 shows the percent distribution of the patients in 
each stage of CKD. The highest number of the patients belonged to stage 4 (26 
patients, 43.3%) followed by stage 3 (19 patients, 31.7%), stage 5 (8 patients, 
13.3%), and then stage 2 (7 patients, 11.7%). Stage1 was not encountered in 

















Stage 5Stage 4Stage 3Stage 2Stage 1
Stages of CKD
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Table 4.3 illustrates the duration of CKD in the patients. The results show 
the mean, minimum and maximum of the period of the disease in different 
stages of CKD. The lowest duration was found in stage 2 (47±2 months), 
followed by stage 4 (55±42 months), stage 3 (56±37 months), and then by 
stage 5 (62±29 months). In general, the minimum duration of the disease in the 
studied patients was 3 months and the maximum was 120 months.  
 
Table 4.3 Duration of chronic kidney disease in the patients 
Stage of CKD Duration/month Mean ± SD Minimum Maximum 
2 47 ± 2 42 48 
3 56 ± 37 10 120 
4 55 ± 42 3 120 
5 62 ± 29 24 90 
 
 
4.3 Traditional CVD risk factors 
 Participants from both groups were investigated for some traditional 
CVD risk factors including diabetes, hypertension, physical inactivity, BMI, and 
family history of CVD. As shown in Table 4.4, no diabetic children were 
encountered in the study population. Hypertension was obvious in the patient 
group and was evident in 28 (47.0%) patients. Thirty (50.0%) patients were 
physically inactive, while physical inactivity was lower in control group and 
constituted 13 (25.0%) of controls. Body mass index is divided into groups as 
recommended by the WHO: Underweight <18.5 kg/m2, normal weight 18.5-24.9 
kg/m2, overweigh 25-29.9 kg/m2, obesity ≥ 30 kg/m2, morbid obesity > 40.0 
kg/m2 (World Health Organization, 2000). Accordingly, the results showed that 
10 (16.7%) patients had normal weight and 50 (83.3%) were of underweight 
compared to 13 (25.0%) normal weight controls and 39 (75.0%) of underweight. 
Other BMI groups were not found in the sample population. The percentage of 
patients with family history of CVD (37.0%) was of nearly equal percentage of 
controls (38.0%).  
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Table 4.4. Traditional cardiovascular disease risk factors among 
patients and controls 
 
Patients (n=60) Controls (n=52) Traditional CVD risk factors 
No. (%) No. (%) 
Diabetes     
Yes 0 (0.0) 0 (0.0) 
No 60 (100.) 52 (100.) 
Hypertension     
Yes 28 (47.0) 0 (0.0) 
No 32 (53.0) 52 (100.) 
Physical inactivity     
Inactive 30 (50.0) 13 (25.0) 
active 30 (50.0) 39 (75.0) 
BMI*    
Normal weight  10 (16.7) 13 (25.0) 
Underweight 50 (83.3) 39 (75.0) 
Family history of CVD     
Yes 22 (37.0) 20 (38.0) 
No 38 (63.0) 32 (62.0) 
        *BMI: Body mass index.  
         Normal weight =18.5-24.9 BMI (kg/m2). Underweight <18.5 BMI (kg/m2) 
 
Table 4.5 shows the frequency of some traditional CVD risk factors 
including hypertension, physical inactivity and BMI in various CKD stages. In 
general, there is a progressive increase in hypertension with CKD stages 
showing percentages of 42.8%, 47.4%, 38.5% and 50.0% in stages 2, 3, 4 and 
5, respectively. Physical inactivity was also increased as CKD developed. The 
percentages of inactive patients were 0.0%, 21.1%, 69.2%, and 100% in stages 
2, 3, 4, and 5, respectively. Obesity, as a traditional risk factor was not present 
since most of the patients were underweight. Results showed that 71.4%, 
89.5%, 76.9%, and 100% of patients in stages 2, 3, 4, and 5, respectively were 
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    Table 4 .5. Distribution of some traditional cardiovascular  
    disease risk factors with respect to the chronic kidney disease stages 
 
Stage of CKD 
2 3 4 5 Traditional CVD risk factors 
No. (%) No. (%) No. (%) No. (%) 
Hypertension           
  Yes 3 (42.8) 9 (47.4) 10 (38.5) 4 (50.0) 
  No 4 (57.2) 10 (52.6) 16 (61.5) 4 (50.0) 
Physical inactivity         
  Inactive 0 (0.0) 4  )21.1(  18 (69.2) 8 (100) 
  Active 7 (100) 15 (78.9) 8 (30.8) 0 (0.0) 
BMI*       
  Normal weight 2   ) 28.6(  2 (10.5)  6 (23.1)  0 (0.0)  
  Underweight 5 (71.4) 17 (89.5) 20 (76.9) 8 (100) 
          
 
Table 4.6 shows the mean values of cholesterol, triglycerides, HDL, and 
LDL in patients and controls. As compared to the controls, the patients showed 
significantly higher mean values of cholesterol (163.6±38.9 vs. 141.8±24.2 
mg/dl, p=0.001), triglycerides (145.5±67.1 vs. 82.9±35.7 mg/dl, p=0.000) and 
LDL (92.6±31.9 vs. 72.5±19.0 mg/dl, p=0.000). Meanwhile the patients showed 
lower level of HDL than controls (41.9±11.0 vs. 52.7±11.7 mg/dl, p=0.000). 
 
 
Table 4.6. Lipid profile (cholesterol, triglycerides, HDL, and LDL) in 
patients and controls 
 
Lipid profile Patient (n=60)   Mean ±SD 
Control (n=52)    
Mean ±SD t 
p-
value 
Cholesterol (mg/dl) 163.6 ± 38.9 141.8 ± 24.2 3.5 0.001 
Triglycerides (mg/dl) 145.5 ± 67.1 82.9 ± 35.7 3.52 0.000 
LDL (mg/dl) 92.6 ± 31.9 72.5 ± 19.0 3.97 0.000 
HDL (mg/dl) 41.9 ±11.0 52.7 ± 11.7 -5.03 0.000 
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The mean values of cholesterol, triglycerides, HDL, and LDL at different 
stages of CKD in the patients are presented in Table 4.7. Generally, the results 
showed a gradual increase in the levels of cholesterol in stages 2, 3, 4, and 5 
with means of 160.3±50.8, 166.9±48.6, 155.2±28.8, and 186±25.7 mg/dl, 
respectively. The mean values of triglycerides were also increased as CKD 
progressed with means of 117.7±8.0, 120.3±64.5, 153.4±54.7, and 204±99.2 
mg/dl in stages 2, 3, 4, and 5, respectively. Also, gradual increase was 
observed in LDL with means of 96.7±40.8, 97.3±40.0, 83±22.3, and 109±22.6 
mg/dl in stages 2, 3, 4, and 5, respectively. On the other hand, HDL generally 
showed gradual decrease as CKD progressed with mean values of 39.7±12.8, 
45.6±7.5, 41.5±13.2, and 36.1±5.8 mg/dl in stages 2, 3, 4, and 5, respectively.    
 
 
Table 4.7. Relation between lipid profile and chronic kidney disease stages 
 
Stage of CKD 
2 3 4 5 Lipid profile 
Mean ±SD Mean ±SD Mean ±SD Mean ±SD 
Cholesterol (mg/dl) 160.3 ± 50.8 166.9 ± 48.6 155.2 ± 28.8 186 ± 25.7 
Triglycerides (mg/dl) 117.7 ± 8.0 120.3 ± 64.5 153.4 ± 54.7 204 ± 99.2 
HDL (mg/dl) 39.7 ± 12.8 45.6 ± 7.5 41.5 ± 13.2 36.1± 5.8 




4.4 Chronic kidney disease- specific CVD risk factors 
 
The participants were investigated for some of CVD risk factors that are 
considered specific to CKD such as anemia, inflammation, Ca x P product, 
hypoalbuminemia, and albuminuria. Table 4.8 shows that most of the patients 
were anemic (76.7%), while anemia was less frequent in the control group 
(15.4%). Inflammation (CRP ≥6 mg/l) had higher percentage (40.0%) in 
patients as compared to controls (5.8%). Ca x P product also showed higher 
percentage (15.0%) in the patients as compared to the controls (2.0%). The 
results also showed that 6.7% of the patients had low serum albumin 
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 (hypoalbuminemia), while all controls had normal serum albumin. Regarding 
albuminuria, the majority of the patients (91.7%) had albuminuria; 29.2% had 
microalbuminuria (ACR 30-300 mg/g), and 62.5% had macroalbuminuria (ACR 
>300 mg/g). Albuminuria was not evident in any of the control subjects.   
 
Table 4.8. Chronic kidney disease- specific cardiovascular disease risk factors 
in patients and controls 
Patient (n=60) Control (n=52) CKD-specific CVD risk 
factors No. (%) No. (%) 
Anemia     
   Anemic 46 (76.7) 8 (15.4) 
   Normal 14 (23.3) 44 (84.6) 
Inflammation     
   Positive 24 (40.0) 3 (5.8) 
   Negative 36 (60.0) 49 (94.2) 
CaXP product (mg2/dl2)     
   ≥ 65 9 (15.0) 1 (2.0) 
   < 65 51 (85.0) 51 (98.0) 
Hypoalbuminemia     
   Yes 4 (6.7) 0 (0.0) 
   No 56 (88.3) 52 (100) 
Albuminuria     *(Patient: n=48)  Control (n=52) 
  Microalbuminuria 14 (29.2) 0 (0.0) 
  Macroalbuminuria 30 (62.5) 0 (0.0) 
  Normal 4 (8.3) 52 (100) 
      
*Twelve patients couldn’t collect urine because of difficulty in their urine 
voidance. 
 
4.4.1 Anemia, albuminemia, and albuminuria  
Table 4.9 illustrates the differences of the mean for hemoglobin, albumin, 
and ACR between patients and controls. The results indicated that there was a 
significant difference between the means of the patients and the controls for 
hemoglobin (9.8±1.4 vs. 11.9±0.8 g/dl, p=0.000), albumin (4.6±0.6 vs. 4.8±0.2 
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Table 4.9. Means of some chronic kidney disease- specific cardiovascular 
disease risk factors in patients and controls 
CKD-specific CVD risk factors Mean ± SD t p-value 
patient (n=60) 9.8 ±1.4 Hemoglobin (g/dl) 
control (n=52) 11.9 ± 0.8 
-9.16 0.000 
patient (n=60) 4.6 ± 0.6 Albumin (g/dl) 
control (n=52) 4.8 ± 0.2 
-2.54 0.012 
patient (n=48) 3183 ±1792  ACR (mg/g) 




Table 4.10 describes the mean values of hemoglobin, albumin, and ACR 
throughout the various stages of CKD. The results showed general decrease in 
hemoglobin as CKD progresses with means of 10.0±1.7, 10.5±1.2, 9.4±1.3, 
and 9.2±1.8 g/dl in stages 2, 3, 4, and 5, respectively. Albumin shows a stable 
mean (4.6 g/dl) at different stages of CKD, while ACR fluctuated between 
stages with means of 1657±3480, 951±2121, 2521±3090, and 868±  209 mg/g 
in stages 2, 3, 4, and 5, respectively.  
 
Table 4.10. Relation between some chronic kidney disease-specific 
cardiovascular disease risk factors with stages of chronic kidney disease 
 
Stage of CKD 
2 3 4 5 CKD-specific CVD risk factors 
Mean ±SD Mean ±SD Mean ±SD Mean ±SD 
Hemoglobin (g/dl) 10 ±1.7 10.5 ± 1.2 9.4 ± 1.3 9.2 ± 1.8 
Albumin (g/dl) 4.6 ± 0.4 4.6± 0.8 4.6 ± 0.5 4.6 ± 0.4 
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Table 4.11 shows the differences of the mean for hemoglobin, Albumin, 
and ACR within stages of CKD of the patients. The results of ANOVA test 
showed that there was a significant difference between the means of 
hemoglobin among the stages of CKD (p=0-.033). On the other hand, the 
difference of the means of albumin and ACR was not statistically significant 
(p=0.993 and 0.347, respectively).  
 
 
Table 4.11. Chronic kidney disease-specific cardiovascular disease risk factors 
within stages of chronic kidney disease 
 
CKD-specific CVD 
risk factors Source df F p-value 
Between Groups 3 Hemoglobin (g/dl) 
Within Groups 56 
3.12 0.033 
Between Groups 3 Albumin (g/dl) 
Within Groups 56 
0.03 0.993 
Between Groups 3 ACR (mg/g) 




4.4.2 Inflammation among patients and controls 
C-reactive protein among patients and controls was measured by 
qualitative and semi-quantitative latex method. Table 4.12 illustrates the 
frequency of positive and negative CRP in the subjects of the two groups. The 
results showed that 36 (60.0%) of the patients and 49 (94.2%) of the controls 
were CRP-negative (CRP<6 mg/l). Three (5.0%) of the patients and 3 (5.8%) of 
the controls were positive for the lowest titer of CRP (6 mg/l). Other titers of 
CRP in the patient group were represented as: 13 (21.7%) of the patients were 
positive for titer 12 mg/l, 6 (10.0%) were positive for titer 24 mg/l and 2 (3.3%) 
for titer 48 mg/l. 
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Distribution of CRP in the different stages of CKD is illustrated in Table 
4.13. The results of stage 2 CKD patients showed that 4 (57.1%) were CRP-
negative, one (14.3%) was positive with 6 mg/l and 2 (28.6%) were positive 
with 12 mg/l. Stage 3 CKD patients showed that 12 (63.2%) were CRP-
negative, one (5.3%) had 6 mg/l, 4 (21.1%) had 12 mg/l, one (5.3%) had 24 
mg/l, and one (5.3%) had 48 mg/l. Stage 4 CKD patients showed that 18 
(69.2%) of the patients in this stage were CRP-negative, 4 (15.4%) had 12 
mg/l, 3 (11.5%) had 24 mg/l, and one (3.8%) had 48 mg/l. Stage 5 CKD 
patients showed that 2 (25.0%) of this category patients were CRP-negative, 1 
(12.5%) had 6 mg/l, 3 (37.5%) had 12 mg/l, and 2 (25.0%) had 24 mg/l. The 
results showed that stage 5 had the highest percentage of CRP positive 
patients (75.0%), followed by stage 2 with 42.9%, stage 3 with 36.8%, and 




Table 4.13 C-reactive protein with respect to the chronic kidney disease 
stages  
CRP titer Patient (n=60) No. (%) 
Control (n=52) 
No. (%) 
Negative <6 mg/dl 36 (60.0) 49 (94.2) 
6 mg/dl 3 (5.0) 3  (5.8) 
12 mg/dl 13 (21.7) _ 
24 mg/dl 6 (10.0) _ 
Positive 
48 mg/dl 2 (3.3) _ 
Stages of CKD 
CRP  2          
No. (%) 
  3         
No. (%) 
4           
No. (%) 
 5         
No. (%) 
Negative <6 mg/dl 4 (57.1) 12 (63.2) 18  (69.2) 2 (25.0) 
Positive ≥6 mg/dl 3 (42.9) 7 (36.8) 8 (30.8) 6 (75.0) 
6 mg/dl 1 (14.3) 1  (5.3) _  1 (12.5) 
12 mg/dl 2 (28.6) 4 (21.1) 4  (15.4) 3 (37.5) 




48 mg/dl  _ 1 (5.3) 1  (3.8) __ 
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4.4.3 Calcium- phosphorus imbalance  
 
Table 4.14 shows the mean values of calcium, phosphorus, and Ca x P 
product in the patients and the controls. The results revealed that patients had 
significantly lower mean values of calcium than controls (9.2±1.4 vs. 10.3±0.4 
mg/dl, p=0.000). In contrast patients had significantly higher means of 
phosphorus compared to controls (5.7±1.3 vs. 5.2±0.5 mg/dl, p=0.006). The 
difference in the means of Ca x P was not significant (52.4±12.9 vs. 53.4±5.3 
mg2/dl2, p= 0.582).   
 
 
Table 4.14. Mean values of calcium, phosphorus and Ca x P product in patients 
and controls 
 
Electrolytes Patient (n=60) Mean ± SD 
Control (n=52)   
Mean ± SD t 
p-
value 
Calcium  (mg/dl) 9.2 ± 1.4 10.3 ± 0.4 -5.57 0.000 
Phosphorus (mg/dl) 5.7 ± 1.3 5.2 ± 0.5 2.79 0.006 
Ca X P  (mg2/dl2) 52.4 ± 12.9 53.4 ± 5.3 -0.55 0.582 
    
 
 
The mean of calcium, phosphorus, and Ca x P product with progression of 
CKD is illustrated in Table 4.15. The results showed a general decrease in the 
mean values of calcium in stages 2, 3, 4, and 5 with means of 9.6±1.1, 9.8±1.4, 
8.8±1.2, and 8.3±1.2 mg/dl, respectively. The results of phosphorus showed 
gradual increase as CKD progresses with means of 4.5±0.4, 5.3±0.7, 6.0±1.4, 
and 7.2±1.2 mg/dl in stages 2, 3, 4, and 5, respectively. Ca x P product was 
also increased in stages 2, 3, 4, and 5 with mean values of 43.6±7.1, 
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Table 4.15. The means of calcium, phosphorus and Ca x P product 
 in various stages of CKD 
Stage of CKD 
2 3 4 5 Electrolytes 
Mean± SD Mean± SD Mean± SD Mean± SD 
Calcium  (mg/dl) 9.6 ± 1.1 9.8 ± 1.4 8.8 ± 1.2 8.3 ± 1.2 
Phosphorus (mg/dl) 4.5 ± 0.4 5.3 ± 0.7 6.0 ± 1.4 7.2 ± 1.2 
Ca X P (mg2/dl2) 43.6 ± 7.1 52.6 ± 12.8 52.6 ± 13.7 59.2 ± 11.4 
 
 
Table 4.16 illustrates the results of ANOVA test to show the differences 
of the means for calcium, phosphorus, and Ca x P product within stages of 
CKD in the patient group. The results revealed significant differences between 
the means of calcium and phosphorus among the stages of CKD, with p=0.017 
and 0.000, respectively. However, the difference of the means of Ca x P 
product was not statistically significant (p= 0.138). 
 
Table 4.16. The difference of the means of calcium, phosphorus and ca x p 
product within CKD stages 
Variable Source df F p-value 
Between Groups 3 Calcium (mg/dl) 
Within Groups 56 
3.71 0.017 
Between Groups 3 Phosphorus (mg/dl) 
Within Groups 56 
8.20 0.000 
Between Groups 3 Ca X P (mg2/dl2) 
Within Groups 56 
1.91 0.138 
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Cardiovascular disease is frequently associated with CKD. Cardiac 
problems  are more clear in ESRD and dialysis patients, some of the CVD risk 
factors are frequent and appear early in CKD. Detection and treatment of CVD 
risk factors is important to control the progression of the disease, since some of 
these risk factors are treatable and controllable. 
 
5.1 Characteristics of the study population 
5.1.1 Socio-demographic characteristics of the study population 
          The present study was conducted on 60 predialysis CKD patients aged ≤ 
12 years old in the Nephrology Department of Abd El-Aziz El-Rantisy 
specialized pediatric hospital. Healthy control group was also included in the 
study. The study showed that the male sex (66.7%) was higher than female. 
Age group 9-12 years was more frequent followed by age group 5-8 years and 
then age group 1-4 years and this reflects the progressive nature of the 
disease. The distribution of the subjects by area showed that Gaza city had 
higher distribution, North region showed nearly equal distribution of subjects 
with South region. Population density and presence of Abd El-Aziz El-Rantisy 
specialized pediatric hospital in Gaza city may be the cause of the higher 
number of subjects from Gaza city. Educational level of participants revealed 
high distribution of illiterate (less than one year of education), subjects under 7 
years of age and those without education belonged to this group. Patients with 
other educational levels (1-3 and 4-6 years) showed about similar distribution.        
 
5.1.2 Height, weight, systolic and diastolic blood pressure among patients 
and controls 
The study showed statistically significant differences between patients and 
controls with respect to height, weight, systolic and diastolic blood pressure, 
where the mean values indicated that the patients were shorter, had lower 
weight, higher systolic and diastolic blood pressure. This result is congruent to 
that of Litwin et al. (2005) who found that the patients were significantly smaller 
and lighter and had higher blood pressure than control subjects. Other studies 
have indicated that CKD in growing children leads to a state of impaired growth 
due to altered metabolic status and defective growth hormone action 
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(Muthukrishnan et al., 2007), and that high blood pressure is a leading 
cause of CKD in adults and contributes to the worsening of CKD in children. 
High blood pressure can also be a complication of kidney disease (NKF, 2009).  
 
5.2 Urea, creatinine, ACR, and GFR among patients and controls 
The results showed that there are statistically significant differences 
between patients and controls with regard to urea, creatinine, ACR, and GFR. 
In contrast to the controls (whose results were in the recommended reference 
range) all patients had abnormal findings (higher urea, creatinine, ACR, and 
lower GFR). The majority of them had different degrees of kidney damage as 
shown by the results of ACR. The duration time of CKD in the patients of this 
study showed that all patients had ≥ 3 months. The results of GFR, ACR, and 
duration time of the disease were used in defining and classifying the CKD 
patients of the study according to NKF-KDOQI guidelines (NKF, 2002).  
 
 
5.3 Stages of CKD in the patients  
Patients of the study were classified into 1 to 5 stages as recommended 
by NKF-KDOQI. Twelve patients couldn't collect urine because of difficulty in 
their urine voidance; the 12 cases belonged to stage 4 and 5 of CKD. Four 
patients (in stage 3) had normal ACR while other patients had abnormal ACR 
(albuminuria). The results showed that the patients enrolled in this study could 
be classified into 4 stages of CKD (stage 2, 3, 4, and 5) where stage 1 was not 
present. Stage 4 had higher incidence, followed by stage 3, then stage 5 and 
stage 2. The decreased presentation of stage 5 in the study population is due 
to initiation of hemodialysis or peritoneal dialysis for many of stage 5 patients 
and in some cases death of the patients before reaching stage 5. Absence of 
stage 1 and reduced number of stage 2 patients in the study population is due 
to low patient's number in these stages referred and hospitalized in the 
Nephrology Department, since the disease in such early stages is  
asymptomatic and criteria of kidney impairment is very mild  especially in stage 
1. Unfortunately no data regarding the prevalence of CKD and CKD stages is 
available in our populations to compare the study findings. This is due to 
underreporting of such diseases in Gaza strip, so frequent documentation of 
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such serious diseases are needed, especially among children. The National 
Health and Nutrition Examination Surveys in 1999-2004 in the USA estimated 
higher prevalence of stage 3 followed by stage 2, 1 and stage 4 represented 
lowest prevalence, where stage 5 was excluded (Coresh et al., 2007). In 
another study that included stages 3, 4, and 5 indicated that stage 3 had higher 
prevalence followed by stage 4 and then stage 5 (Annear et al., 2008). Essig et 
al. (2007) in their study on early CKD stages (1, 2, and 3) found that stage 3 
had higher distribution followed by stage 2 and then stage 1. 
    
5.4 Distribution of traditional CVD risk factors in study sample 
5.4.1 Hypertension  
The present study showed that there is association between hypertension 
and CKD. Forty seven percent of patients had a history of hypertension and 
were given the anti-hypertensive drugs. The means of systolic and diastolic 
blood pressure were significantly higher in patients as compared to controls. 
The relationship between hypertension and progression of CKD was clear 
within stages of CKD since the frequency of hypertensive patients gradually 
increased through stages 2, 3 and 5. The results  are in agreement with those 
of other authors  who found an association between hypertension and CKD and 
showed that hypertension was frequent in all stages of CKD (Goicoechea et al., 
2005; Zhang et al., 2006; Parikh et al., 2006; Essig et al., 2007; Levin, 2008 
and Shroff, 2009). An analysis of blood pressure in the North American 
Pediatric Renal Transplant Cooperative Study (NAPRTICS) database 
estimated the prevalence of hypertension among children with CKD as being 
closer to 50% and demonstrated that renal function in hypertensive children 
with CKD deteriorated significantly more rapidly than in normotensive children, 
and raises the possibility that improved blood pressure control may be one 
method of slowing the progression of CKD in this population (Mitsnefes et al., 
2003). In another study that was carried out on CKD adult patients not receiving 
renal replacement therapy showed that 76% of patients had history of 
hypertension (Wheeler et al., 2003). Locatelli et al. (2003) found out that 
hypertension plays a major role in determining cardiac damage at all stages of 
CKD, including the dialytic phase. 
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5.4.2 Physical inactivity, obesity and family history of CVD  
Half of the patients of the present study were physically inactive. 
Frequency of physical inactivity among patients was two-fold higher as 
compared to controls. With respect to CKD stages the results showed that all 
cases in stage 2 were active, inactivity was increased in stages 3 and 4, and in 
stage 5 all cases were inactive. This indicates a positive correlation between 
physical inactivity and CKD progression. Stein and his colleagues reported in 
their study that physical inactivity was associated significantly with CKD (Stein 
et al., 2006). Moreover, Shlipak et al. (2005) stated that low physical activity is 
a predictor of cardiovascular mortality in persons with chronic kidney disease. 
In the present study BMI was used as an indicator for obesity. The results 
showed that the frequency of underweight among patients was higher than 
controls. Overweight and obesity were not encountered in the study population. 
Chronic kidney disease stages in the study revealed that the frequency of 
underweight increased as GFR declined through stages 2, 4 and 5. Our results 
are in accordance with the study of Litwin et al. (2005) who showed that 
patients with CKD were lighter and had lower BMI than controls. Other studies, 
however, reported contradictory results (Ishizaka et al., 2007 and Kramer, 
2006), they found that obesity was a risk factor for CKD progression and there 
was an increase in BMI as GFR declined. The variation in the results may be 
because we studied the presence of obesity in our study population who are 
already suffering from CKD and not CKD as a sequel to obesity. Additionally, 
the prevalence of underweight in both the controls and study population may 
reflect the nutritional status or behavior of our children population. 
 In studying family history of CVD as a risk factor of CVD in the study 
population, the results indicated that there was no difference between patients 
and controls since they had nearly equal percentages of subjects with family 
history of CVD. This observation indicates that there is a genetic factor in 
causing CVD.  
 
5.4.3 Dyslipidemia  
           In the general population, high plasma concentrations of LDL 
cholesterol, low concentrations of HDL cholesterol, and to some extent high 
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total triglyceride concentrations are associated with increased atherosclerotic 
CVD risk (Wilson et al., 1998). There seems to be a gradual shift to the uremic 
lipid profile as kidney function deteriorates (Kronenberg et al., 2002). Uremic 
lipid profile shows dyslipidemia with elevated cholesterol, triglyceride and 
decreased HDL. Elevated plasma LDL cholesterol concentration is common in 
nephrotic syndrome but is not a typical feature of patients with advanced CKD 
(Bonnie et al., 2007).    
Our study showed significant increase in total cholesterol, triglycerides and 
LDL in the patients as compared to the controls. The results also revealed 
significantly lower level of HDL in the patients. A gradual shift to the uremic lipid 
profile as CKD progresses was evident in CKD stages of the present study 
(gradual increase of cholesterol, triglycerides, LDL, and decrease in the levels of 
HDL). This finding is in agreement with other studies that assessed the 
association between CKD and some CVD risk factors including dyslipidemia. 
Studies conducted on older patients in different stages of CKD found that the 
CKD patients had high prevalence of dyslipidemia (Locatelli et al., 2003; Zhang 
et al., 2006; Shroff, 2009). Wheeler et al. (2003) also showed that there is an 
association between CKD and dyslipidemia with reduced LDL, elevated 
triglyceride and decreased HDL levels. In another study, Parikh et al. (2006) 
indicated that CKD patients were more likely to have low levels of HDL, and high 
triglyceride levels. In a study on children with CKD, the control group and patient 
groups were comparable in terms of dyslipidemia, the patients had significantly 
higher triglycerides levels than controls, whereas total cholesterol and LDL were 
selectively increased in the dialysis group (Litwin et al., 2005).  
                             
5.5 Chronic kidney disease specific CVD risk factors 
5.5.1 Albuminuria  
Elevation of albuminuria is related to higher risk of subsequent 
development of clinical nephropathy and that increased albuminuria is 
associated with higher risk for CVD events (Mogensen, 1984). More than one 
method can be used to determine urine albumin execration (KDOQI, 2004). In 
the present study ACR in spot morning urine samples was used to measure 
albuminuria. The results showed that there was association between CKD and 
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increased level of ACR with significant difference between patients and 
controls. Macroalbuminuria (ACR> 300 mg/g) was predominant in the patients 
followed by microalbuminuria (ACR= 30-300 mg/g), while few patients (8.3%) 
had normal albuminuria (ACR<30 mg/g). Albuminuria showed irregularity 
between stages of CKD, i.e, ACR levels fluctuated between stages. This 
irregularity can be attributed to the cause of the renal disease, since 
albuminuria varies according to the cause of the renal disease (Sarnak et al., 
2003). Our findings are congruent with other studies, which suggested that 
albuminuria is a common feature in CKD and is related to the underlying 
glomerular or interstitial damage (Amaresan, 2005). Zhang et al. (2006) 
reported that albuminuria was frequent even in early stages of CKD. Several 
investigators have shown that there is a continuous association between the 
level of albuminuria and the risk for CVD and, thus, macroalbuminuria or clinical 
proteinuria is associated with a higher risk for CV morbidity and mortality than 
microalbuminuria. The presence of macroalbuminuria is a clear manifestation of 
overt nephropathy and is associated with faster deterioration of kidney function 
(Agewall et al., 1997; Gerstein et al., 2001; Yuyun et al., 2004).  
 
5.5.2 Anemia  
Anemia has been shown to be significantly associated with LVH in both 
dialysis patients and patients with early CKD, suggesting that anemia is 
primarily implicated in the development of LVH in CKD (Silverberg et al., 1998 
and Levin et al., 1999). Anemia is a potentially modifiable risk factor; its 
treatment seems to have a more beneficial effect on LVH regression if it is 
given as early as possible during the course of CKD and before patients have 
reached ESRD (Locatelli et al., 2003). In the present study, the majority of 
patients were anemic and the mean values of hemoglobin showed significant 
decrease in patients as compared to controls. The results showed continuous 
decrease of hemoglobin in stages 3, 4 and 5, which indicate an association 
between anemia and CKD progression in the study population. These results 
are congruent with that of other authers who found association between CKD 
and low hemoglobin or haematocrit in predialysis CKD patients (Locatelli et al., 
2003 and Wheeler et al., 2003). Goicoechea et al. (2005) in their study on CKD 
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patients, and after a mean follow-up of 22.3 months, found that some of the 
patients had a cardiovascular event; the patients who suffered from 
cardiovascular event were older, more anemic, and had higher pulse pressure. 
 
5.5.3 Calcium – phosphorus metabolism  
Patients included in the present study showed significantly lower total 
calcium and higher phosphorus compared to the controls. With respect to 
stages of CKD, the results showed a gradual decrease in total calcium and a 
progressive rise in phosphorus levels as CKD progresses. The study showed 
that there was no statistically significant difference between patients and 
controls with regard to the means of Ca x P product, since there was nearly 
equal means of Ca x P product of controls (who had normal calcium and 
phosphorus levels) and patients (who had lower calcium and higher 
phosphorus levels). The distribution of abnormal Ca x P product (>65 mg2/dl2), 
however, was higher in patients than controls. The mean values of Ca x P 
product showed continuous increase in stages 2, 3, 4, and 5. This finding of 
calcium- phosphorus metabolism indicates the association of progressive 
nephron loss with phosphorus retention and hypocalcemia in pre-dialysis 
patients. 
Hypercalcemia can develop when patients (mainly in late stages of CKD 
and dialysis) are given calcium and/or vitamin D and due to increased levels of 
PTH, which increases calcium and phosphorus ion product.  
Hyperparathyroidism along with hyperphosphatemia and increased calcium 
phosphate ion product are identified as independent cardiovascular risk factors 
(Moe and Drueke, 2003). The results of the present study are in accordance 
with Zehnder et al. study which was carried out on patients with stages 3-5 and 
showed that serum phosphorus and PTH concentrations were elevated among 
patients as compared to controls (Zehnder et al., 2007). Locatelli et al. (2003) in 
their study showed that calcium–phosphate disorders were important 
cardiovascular risk factors in CKD. Abo-shamala (2008) in his study of PTH, 
calcium and phosphorus levels in hemodialysis patients,  reported that there 
were statistically significant differences in the mean levels of serum PTH, 
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calcium x phosphorus product, phosphorus and ionized calcium between the 
patients and the controls.  
 
5.5.4 Inflammation 
In the present study, qualitative and semi- quantitative detection of CRP 
were used to estimate the inflammation status in the subjects of the study. The 
results showed that patients had higher percentages of positive CRP (CRP >6 
mg/l) than controls.  Distribution of patients with positive CRP showed variation 
in the stages of CKD. Stage 5 had the highest percentages of CRP positive 
patients, and decreasing through stage 2, stage 3 and then stage 4. The rise in 
inflammatory state of CKD (especially in stage 5) may be due to an increase of 
uremia (which  is a state of chronic inflammation), reduced renal clearance of 
cytokines, and accumulation of advanced glycation end products (Stenvinkel et 
al., 1999 and Zoccali et al., 2000). Inflammation and increased level of CRP in 
patients with CKD was also observed in other studies, which reported that 
patients with CKD had elevated levels of CRP (Wheeler et al., 2003 and Shroff, 
2009). 
There is growing evidence that inflammation probably plays a key role in 
the initiation and progression of the atherosclerotic process (Ross, 1999). High 
serum concentrations of markers of systemic inflammation (including C-reactive 
protein and interleukin-6) have been associated with atherosclerosis 























Chronic kidney disease, with its high burden of CVD risk factors, 
represents an important public health concern. The identification of an 
individual with CKD should alert the practitioners to a large underlying burden 
of potentially modifiable CVD risk factors. 
 
The study showed a significant association between a number of CVD 
risk factors and CKD, such CVD risk factors include hypertension, 
dyslipidemia (increased total cholesterol, triglycerides, LDL, and decreased 
HDL), physical inactivity, anemia, albuminuria, hypoalbuminemia, and 
inflammation. This positive association was shown in all stages of CKD prior 
to dialysis.  
 
Some CVD risk factors revealed progressive nature such as 
hypertension, physical inactivity, dyslipidemia, and anemia, since these 
factors were increased as CKD progressed.  
 
Other studied CVD risk factors, including obesity, and family history of 
CVD, did not show statistically significant association with CKD in the patients 
of the study.  
 
Although, Ca X P product showed no statistical significant association 
with CKD in the study population, the patients showed significantly lower total 
calcium and higher phosphorus as compared to the controls. 
 
         Other studied CVD risk factors were not present in the study population 
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6.2 Recommendations 
• Patients with CKD should be classified into stages according to the NKF-
KDOQI and routinely tested for GFR and ACR levels to observe the 
progression of the disease. 
  
• Regular evaluation of CVD risk factors in CKD patients is needed for early 
diagnosis of these risk factors. 
 
• Aggressive management of CVD risk factors, especially modifiable risk 
factors such as: hypertension, anemia, dyslipidemia, and physical 
inactivity in early stages, is important in controlling the disease 
progression and may reduce the CVD events. 
 
• Increase attention to CVD events, even at early stages of CKD, not only 
by nephrologists, but more importantly by cardiologists and the general 
medical community. 
 
• Encourage the general physician for early referral of the patients with 
primary kidney deterioration to the nephrology centers will enable early 
prevention of CVD. 
 
• Increase awareness of CKD and its complications and methods of control 
and prevention, on the level of public community, is important in reducing 
its adverse consequences.    
 
• Further studies are needed to investigate other emerging cardiovascular 
risk factors, such as homocysteinaemia, High sensitivity C-reactive 
protein, lipoprotein (a), and oxidative stress. ultrasonographic 
measurements such as the measurement of increased intima-media 
thickness (IMT) of large arteries, is important as early marker and 
sensitive predictor of CVD events in CKD patients. 
 
• Large study is needed for measurement of BMI of our children in pediatric 
age, since the majority of the study subjects were underweight.   
 
• Regular reporting and documentation on the incidence and prevalence of 
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Cross- sectional Study Questionnaire for Cardiovascular Risk 
Factors in Chronic Kidney Disease Children 
 
Personal data:  
 
Name:                                            Serial No.:                                   
                                
 Age:                                               Gender: 
   




Height (cm):                                     Weight (kg):  
  
Systolic BP:                                          Diastolic BP: 
   
Body Mass Index:                 
 
 




Time from diagnosis (month):  
Compliance of medication or treatments: □ Low    □Moderate    □High  
Has Diabetes:             □Yes    □No        
Has Hypertension:          □Yes    □No 
Hypertension is regular:        □Yes    □No 




Activities of daily living:         □ Low           □Moderate         □High           






Get more than 30 minutes of physical activity at least 3 days per          
week:           □Yes          □No                         
 
 
History of CVD in the patients, family 
 
Any one of the patient's close relatives has: 
Stroke:                 □ Yes            □No  
Myocardial infarction:     □ Yes            □No 
Heart failure:          □ Yes           □No 
Angina:             □ Yes            □No 
Cardiac catheterization:     □ Yes            □No 
Open heart operation:         □ Yes            □No 
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